<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X11428516</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X11428516</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Policy Implications of Adjusting Randomized Trial Data for Economic Evaluations</article-title>
<subtitle>A Demonstration from the ASCUS-LSIL Triage Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Campos</surname><given-names>Nicole G.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Castle</surname><given-names>Philip E.</given-names></name>
<degrees>PhD, MPH</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Schiffman</surname><given-names>Mark</given-names></name>
<degrees>MD, MPH</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Jane J.</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X11428516">Center for Health Decision Science, Harvard School of Public Health, Boston, MA (NGC, JJK)</aff>
<aff id="aff2-0272989X11428516">Center of Excellence for Health Disparities Research–El Centro, School of Nursing and Health Studies, University of Miami, Coral Gables, FL (NGC)</aff>
<aff id="aff3-0272989X11428516">American Society for Clinical Pathology Institute, Washington, DC (PEC)</aff>
<aff id="aff4-0272989X11428516">Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD (MS)</aff>
<author-notes>
<corresp id="corresp1-0272989X11428516">Nicole G. Campos, PhD, P.O. Box 248153, Coral Gables, FL 33124-3850; telephone: (305) 284-2895; e-mail: <email>gastin@post.harvard.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>400</fpage>
<lpage>427</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>11</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>8</month>
<year>2011</year>
</date>
</history>
<abstract>
<p><bold>Background.</bold> Although the randomized controlled trial (RCT) is widely considered the most reliable method for evaluation of health care interventions, challenges to both internal and external validity exist. Thus, the efficacy of an intervention in a trial setting does not necessarily represent the real-world performance that decision makers seek to inform comparative effectiveness studies and economic evaluations. <bold>Methods.</bold> Using data from the ASCUS-LSIL Triage Study (ALTS), we performed a simplified economic evaluation of age-based management strategies to detect cervical intraepithelial neoplasia grade 3 (CIN3) among women who were referred to the study with low-grade squamous intraepithelial lesions (LSIL). We used data from the trial itself to adjust for 1) potential lead time bias and random error that led to variation in the observed prevalence of CIN3 by study arm and 2) potential ascertainment bias among providers in the most aggressive management arm. <bold>Results.</bold> We found that using unadjusted RCT data may result in counterintuitive cost-effectiveness results when random error and/or bias are present. Following adjustment, the rank order of management strategies changed for 2 of the 3 age groups we considered. <bold>Conclusions</bold>. Decision analysts need to examine study design, available trial data, and cost-effectiveness results closely in order to detect evidence of potential bias. Adjustment for random error and bias in RCTs may yield different policy conclusions relative to unadjusted trial data.</p>
</abstract>
<kwd-group>
<kwd>economic evaluation</kwd>
<kwd>randomized trial</kwd>
<kwd>bias</kwd>
<kwd>cervical cancer</kwd>
<kwd>human papillomavirus</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May–June 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Although the randomized controlled trial (RCT) is considered the most reliable method for evaluation of health care interventions,<sup><xref ref-type="bibr" rid="bibr1-0272989X11428516">1</xref>,<xref ref-type="bibr" rid="bibr2-0272989X11428516">2</xref></sup> the use of RCT data for estimating the health impact of interventions for economic evaluations may be problematic.<sup><xref ref-type="bibr" rid="bibr3-0272989X11428516">3</xref><xref ref-type="bibr" rid="bibr4-0272989X11428516"/>–<xref ref-type="bibr" rid="bibr5-0272989X11428516">5</xref></sup> Beyond threats to internal validity, including random error and bias, there are challenges to external validity as well. Due to strict exclusion criteria invoked in subject selection,<sup><xref ref-type="bibr" rid="bibr3-0272989X11428516">3</xref></sup> and high intensity of testing and care under protocol,<sup><xref ref-type="bibr" rid="bibr4-0272989X11428516">4</xref></sup> intervention efficacy in a trial setting does not necessarily represent the real-world performance that decision makers seek to inform analyses of comparative effectiveness.</p>
<p>Eddy notes that, in the process of evaluating medical technologies, a common heuristic in dealing with threats to validity is to either 1) designate the bias as “acceptable” and take a study’s findings at “face value” or 2) determine the bias is “unacceptable” and disregard the study.<sup><xref ref-type="bibr" rid="bibr6-0272989X11428516">6</xref></sup> As an alternative to these extreme approaches, Eddy argues for a middle ground that involves estimating the magnitude of biases and adjusting for them in a formal way, relying on the adjusted results for decision-making purposes. Using this general framework, Rittenhouse has adjusted RCT data to demonstrate the impact of strict exclusion criteria on cost-effectiveness analysis.<sup><xref ref-type="bibr" rid="bibr3-0272989X11428516">3</xref></sup> Other economic evaluations have adjusted RCT data to correct for the artificial conditions under which intervention effectiveness is measured.<sup><xref ref-type="bibr" rid="bibr5-0272989X11428516">5</xref>,<xref ref-type="bibr" rid="bibr7-0272989X11428516">7</xref></sup></p>
<p>We use data from the atypical squamous cells of undetermined significance (ASCUS)–low-grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS), a randomized multicenter trial, sponsored by the National Cancer Institute (NCI) from 1997 to 2001, to demonstrate the pitfalls of using unadjusted RCT data in a decision analytic model. In this article, we apply Eddy’s general framework to inform an economic evaluation of age-based management protocols for women with LSIL cervical cytology results. We present a simple method of correcting for random error and bias in study design using data from the trial itself and show that such adjustments lead to different policy conclusions relative to unadjusted trial data.</p>
<sec id="section1-0272989X11428516">
<title>The Ascus-Lsil Triage Study (Alts) (<xref ref-type="table" rid="table5-0272989X11428516">Appendix Table 1</xref>)</title>
<p>Approximately 15 carcinogenic types of human papillomavirus (HPV) cause virtually all cases of cervical cancer, but the vast majority of infections are benign and clear within 1 to 2 years of sexual acquisition.<sup><xref ref-type="bibr" rid="bibr8-0272989X11428516">8</xref></sup> Widespread screening with cervical cytology can reduce the incidence of cervical cancer through detection and treatment of precancerous lesions.<sup><xref ref-type="bibr" rid="bibr9-0272989X11428516">9</xref></sup> More than 50 million Pap smears are performed in the United States each year, and more than 5% of results are reported as abnormal.<sup><xref ref-type="bibr" rid="bibr10-0272989X11428516">10</xref></sup> While health care providers generally agree that cytologically diagnosed high-grade squamous intraepithelial lesions (HSILs) should be further evaluated with colposcopy and biopsy, optimal management of approximately 3 million women with cytological results of LSIL and ASCUS<sup><xref ref-type="fn" rid="fn1-0272989X11428516">a</xref></sup> is less straightforward.<sup><xref ref-type="bibr" rid="bibr11-0272989X11428516">11</xref></sup> An LSIL classification indicates an acute HPV infection.<sup><xref ref-type="bibr" rid="bibr12-0272989X11428516">12</xref></sup> Some LSIL heralds the presence of high-grade precancer, histological cervical intraepithelial neoplasia grade 3 (CIN3) (<xref ref-type="fig" rid="fig1-0272989X11428516">Figure 1</xref>). ASCUS is the most common abnormality in the United States, forming the boundary between normal and abnormal cytological interpretations. A sizable fraction of CIN3 and higher are detected by ASCUS cytology due to the commonality of the result and the fact that some represent true abnormalities.<sup><xref ref-type="bibr" rid="bibr12-0272989X11428516">12</xref></sup> Colposcopically directed biopsy to assess disease severity is costly and likely leads to overtreatment of lesions that may spontaneously regress. Yet many clinicians are hesitant to pursue less aggressive follow-up measures for fear of missing CIN3.<sup><xref ref-type="bibr" rid="bibr13-0272989X11428516">13</xref>,<xref ref-type="bibr" rid="bibr14-0272989X11428516">14</xref></sup></p>
<fig id="fig1-0272989X11428516" position="float">
<label>Figure 1</label>
<caption>
<p>Natural history of cervical carcinogenesis. HPV incidence peaks around the time of sexual debut, and while most infections are benign and clear within 1 to 2 years of sexual transmission, some will persist. Persistent infections with any of the 10 to 15 carcinogenic HPV types are at risk of developing into precancer. Histologically confirmed CIN3 is at high risk of progressing to cancer and requires definitive treatment. HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia. From Schiffman and Kjaer,<sup><xref ref-type="bibr" rid="bibr13-0272989X11428516">13</xref></sup> with permission of Oxford University Press.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11428516-fig1.tif"/>
</fig>
<p>ALTS compared 3 methods of managing women with ASCUS or LSIL cytological interpretations<sup><xref ref-type="bibr" rid="bibr15-0272989X11428516">15</xref></sup> for the timely detection of CIN3. Although the treatment threshold in the trial and in current practice is CIN grade 2 and higher (CIN2+), CIN2 is not a reliable indication of precancer; it may be caused by noncarcinogenic HPV types and frequently regresses.<sup><xref ref-type="bibr" rid="bibr8-0272989X11428516">8</xref></sup> CIN3 detection was chosen as the primary outcome of interest because histologically confirmed CIN3 is at high risk of progressing to invasive cancer and requires definitive treatment.<sup><xref ref-type="bibr" rid="bibr16-0272989X11428516">16</xref></sup> The 3 arms of the trial included 1) immediate colposcopy (IC) and directed biopsy (all women were sent to colposcopy at enrollment); 2) conservative management (CM) (women received colposcopy only if enrollment or any follow-up cytology at 6-month intervals was HSIL or above [HSIL+]); and 3) HPV DNA testing with the Hybrid Capture 2 test (HC2) (Qiagen, Gaithersburg, MD) (colposcopy only if the enrollment HC2 test result was positive for carcinogenic HPV or missing or enrollment cytology was HSIL+). IC was considered to have optimal sensitivity (and thus safety against cancer risk) but might lead to costly overtreatment and its sequelae,<sup><xref ref-type="bibr" rid="bibr14-0272989X11428516">14</xref></sup> whereas CM presumably allowed for some lesions to resolve spontaneously but may have posed a greater cancer risk. Detection of carcinogenic HPV was considered as a means of triaging women to colposcopy based on high (carcinogenic HPV+) risk of precancer and cancer.<sup><xref ref-type="bibr" rid="bibr17-0272989X11428516">17</xref></sup> HPV DNA testing could be a useful triage tool if carcinogenic HPV infections are not detected in the vast majority of women with ASCUS or LSIL and if the detection of carcinogenic HPV is sensitive for CIN3.</p>
<p>Cost data were not collected as part of the study. Two published studies, one from a long-term societal perspective<sup><xref ref-type="bibr" rid="bibr18-0272989X11428516">18</xref></sup> and one from the short-term perspective of ALTS,<sup><xref ref-type="bibr" rid="bibr19-0272989X11428516">19</xref></sup> have estimated the cost-effectiveness of management strategies for women in the United States with an ASCUS referral. Both found HPV triage to colposcopy an attractive option for women with ASCUS cytology results, regardless of age. To our knowledge, there are no published studies on the cost-effectiveness of LSIL management in the United States. As of 2009, clinical guidelines in the United States recommend that cervical cancer screening should begin at age 21 years,<sup><xref ref-type="bibr" rid="bibr9-0272989X11428516">9</xref></sup> with referral to colposcopy and biopsy for those with LSIL results.<sup><xref ref-type="bibr" rid="bibr20-0272989X11428516">20</xref></sup> Given the decreasing prevalence of carcinogenic types of HPV as women age, even among those with LSIL cytology results,<sup><xref ref-type="bibr" rid="bibr21-0272989X11428516">21</xref><xref ref-type="bibr" rid="bibr22-0272989X11428516"/>–<xref ref-type="bibr" rid="bibr23-0272989X11428516">23</xref></sup> the present analysis examines the cost-effectiveness of management strategies for LSIL women in ALTS according to age strata to discern whether HPV DNA testing may be an attractive option for triaging older women to colposcopy. We demonstrate how cost-effectiveness results may change following adjustment for random error and bias in trial design.</p>
</sec>
<sec id="section2-0272989X11428516" sec-type="methods">
<title>Methods</title>
<p>All women in ALTS received pelvic examinations, Pap smears, and HPV DNA testing at enrollment and every 6 months for 2 years. After the enrollment pelvic examination and specimen collection, women randomized to the IC arm received same-day colposcopy or, if unable to stay, were given an appointment to return for colposcopy (ideally within 3 weeks).<sup><xref ref-type="bibr" rid="bibr15-0272989X11428516">15</xref></sup> Women randomized to the HPV and CM arms were not triaged to colposcopy until enrollment test results were available several weeks after the enrollment visit. Regardless of study arm, women with a cytology result of HSIL during follow-up were referred to colposcopy or received safety notification. Women diagnosed as CIN2+ by the clinical center or CIN3+ by the quality control (QC) pathology group were treated by excision. At exit, colposcopy was performed on all women to capture any missed disease. The primary study end point was a worst QC pathology diagnosis of CIN3 throughout the 2-year study.<sup><xref ref-type="fn" rid="fn2-0272989X11428516">b</xref></sup> The ALTS protocol was reviewed and approved by institutional review boards at the NCI and each participating clinical center. All study participants provided written informed consent.</p>
<p>The HPV arm for women referred with an LSIL cytology interpretation closed early after an interim analysis revealed that 83% were triaged to colposcopy based on a positive HPV DNA test result.<sup><xref ref-type="bibr" rid="bibr24-0272989X11428516">24</xref></sup> Investigators estimated the high prevalence of carcinogenic HPV infections would limit the usefulness of HPV DNA testing as a triage mechanism for women with LSIL, with the expected cost of HPV testing likely outweighing potential savings from avoiding colposcopy in 20% to 27% of women.<sup><xref ref-type="bibr" rid="bibr24-0272989X11428516">24</xref></sup> An interim safety analysis revealed that CM was not sufficiently sensitive for detection of CIN3 among women with an LSIL referral. Consequently, women in the LSIL CM arm who had not previously been triaged to colposcopy were referred to this procedure at their next visit as the result of a protocol modification in July 1999.<sup><xref ref-type="bibr" rid="bibr25-0272989X11428516">25</xref></sup></p>
<sec id="section3-0272989X11428516">
<title>Study Sample</title>
<p>We restricted the present analysis to the 1572 women in ALTS with a referral interpretation of LSIL. We excluded those with missing QC pathology diagnoses (<italic>n</italic> = 6) as uninformative and women with cancer detected at enrollment (<italic>n</italic> = 4) as a pre-existing condition that was unrelated to the management strategy. We included 1 case of cancer in the CM arm that was not detected until 18 months into the study and was therefore considered a failure of the arm. Our sample included 669 women, 222 women, and 671 women in the IC, HPV, and CM arms, respectively. We stratified women into the following age tertiles: &lt;21 years, 21 to 24 years, and ≥25 years.</p>
</sec>
<sec id="section4-0272989X11428516">
<title>Decision Model</title>
<sec id="section5-0272989X11428516">
<title>Analytic overview</title>
<p>We modified a decision analytic model previously used to evaluate the short-term costs and effectiveness of management strategies for women with ASCUS.<sup><xref ref-type="bibr" rid="bibr19-0272989X11428516">19</xref></sup> An overview of the model is shown in <xref ref-type="fig" rid="fig2-0272989X11428516">Figure 2</xref>.</p>
<fig id="fig2-0272989X11428516" position="float">
<label>Figure 2</label>
<caption>
<p>Model overview. This figure displays the general structure of the decision tree model<sup><xref ref-type="bibr" rid="bibr19-0272989X11428516">19</xref></sup> used to evaluate costs and number of cases of CIN3 detected among women with a referral cytology result of LSIL in ALTS. Management strategies included IC, HPV DNA testing, and CM with up to 3 repeat cytology tests at enrollment, 6 months, and 12 months. Model health state was based on the worst 2-year QC pathology group diagnosis. Triage test results were only relevant in the HPV DNA testing arm (HC2) and CM (cytology) arms, and women were referred to colposcopy for a positive or missing HC2 test result or HSIL+, respectively. Colposcopy results were based on evaluation at clinical centers, with a treatment threshold of CIN2. The outcome was cost per case of CIN3 detected. CIN = cervical intraepithelial neoplasia; LSIL = low-grade intraepithelial lesion; ALTS = ASCUS/LSIL Triage Study; IC = immediate colposcopy; HPV = human papillomavirus; CM = conservative management; HC2 = Hybrid Capture 2; QC = quality control; HSIL = high-grade squamous intraepithelial lesion.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11428516-fig2.tif"/>
</fig>
<p>We conducted this analysis from a payer perspective. Our measure of effectiveness for each management strategy was the number of clinical center diagnoses of CIN2+ (at enrollment for the IC and HPV arms; at enrollment, 6-month, and 12-month visits for the CM arm) among women with a worst 2-year QC pathology group diagnosis of CIN3 because the clinical center diagnosis of CIN2+ led to immediate treatment of women with the primary end point, as it does in real-world practice. Due to the short-term horizon of the trial, we did not discount costs or effectiveness measures, as would be recommended in a cost-effectiveness analysis from a societal perspective.<sup><xref ref-type="bibr" rid="bibr26-0272989X11428516">26</xref></sup> The relative performance of each management strategy was expressed as an incremental cost-effectiveness ratio (ICER), defined as the incremental cost divided by the incremental effectiveness of a strategy compared to the next most costly strategy, after eliminating strategies that were dominated (i.e., more costly and less effective than other strategies or having a higher ICER than more effective strategies). The ICER was expressed as the cost per case of CIN3 detected at the clinical centers.</p>
</sec>
<sec id="section6-0272989X11428516">
<title>Effectiveness data</title>
<p>Primary data from ALTS were used to calculate the probability of events in the model. The proportions of women in each model health state—normal, CIN1, CIN2, and CIN3—were based on worst 2-year QC pathology group diagnosis. The probabilities of a positive triage test result and of a clinical center diagnosis of CIN2+ on biopsy were conditioned on health state. Women who were referred to but did not participate in colposcopy at the specified visit did not incur costs of colposcopy and were not eligible for case detection. Women who missed one or more visits in the CM arm did not incur costs of Pap smear or colposcopy and were not eligible for case detection at the missed visit but could incur such costs or benefit from case detection if they received a Pap smear and referral to colposcopy at a subsequent visit.</p>
<p><xref ref-type="table" rid="table1-0272989X11428516">Table 1</xref> displays the distribution of trial parameters that determine the effectiveness and cost-effectiveness of management strategies by study arm and age tertile. We calculated exact binomial 95% confidence intervals for proportions. Fisher exact tests were used to assess associations between age tertiles (within study arm) and study arms (within age tertile). When <italic>P</italic> &lt; 0.05, a Tukey-type multiple comparison test for proportions was used to discern which groups were significantly different from each other.<sup><xref ref-type="bibr" rid="bibr27-0272989X11428516">27</xref></sup></p>
<table-wrap id="table1-0272989X11428516" position="float">
<label>Table 1</label>
<caption>
<p>Influential Parameters by Study Arm and Age Tertile</p>
</caption>
<graphic alternate-form-of="table1-0272989X11428516" xlink:href="10.1177_0272989X11428516-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">&lt;21 Years<sup><xref ref-type="table-fn" rid="table-fn2-0272989X11428516">a</xref></sup></th>
<th align="center" colspan="2">21–24 Years<sup><xref ref-type="table-fn" rid="table-fn2-0272989X11428516">a</xref></sup></th>
<th align="center" colspan="2">25+ Years<sup><xref ref-type="table-fn" rid="table-fn2-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th align="center" colspan="7">Prevalence of CIN3</th>
</tr>
<tr>
<th/>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>169</td>
<td>13.6 (8.8–19.7)</td>
<td>233</td>
<td>15.0 (10.7–20.3)</td>
<td>267</td>
<td>15.7 (11.6–20.7)</td>
</tr>
<tr>
<td>HPV</td>
<td>69</td>
<td>14.5 (7.2–25.0)</td>
<td>67</td>
<td>16.4 (8.5–27.5)</td>
<td>86</td>
<td>22.1 (13.9–32.3)</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>207</td>
<td>13.0 (8.8–18.4)</td>
<td>219</td>
<td>12.8 (8.7–17.95)</td>
<td>245</td>
<td>15.1 (10.9–20.2)</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.9</td>
<td/>
<td>0.7</td>
<td/>
<td>0.3</td>
</tr>
<tr>
<th align="center" colspan="7">Colposcopic Referrals<sup><xref ref-type="table-fn" rid="table-fn4-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
</tr>
<tr>
<td>IC</td>
<td>169</td>
<td>100.0 (97.8–100.0)</td>
<td>233</td>
<td>100.0 (98.4–100.0)</td>
<td>267</td>
<td>100.0 (98.6–100.0)</td>
</tr>
<tr>
<td>HPV</td>
<td>69</td>
<td>89.9 (80.2–95.8)</td>
<td>67</td>
<td>86.6 (76.0–93.7)</td>
<td>86</td>
<td>80.2 (70.25–88.0)</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>207</td>
<td>15.0 (10.4–20.6)</td>
<td>219</td>
<td>19.2 (14.2–25.0)</td>
<td>245</td>
<td>19.2 (14.45–24.7)</td>
</tr>
<tr>
<td>CM first visit</td>
<td>207</td>
<td>8.7 (5.2–13.4)</td>
<td>219</td>
<td>15.1 (10.6–20.5)</td>
<td>245</td>
<td>11.8 (8.1–16.6)</td>
</tr>
<tr>
<td>CM second visit</td>
<td>187</td>
<td>3.7 (1.5–7.6)</td>
<td>184</td>
<td>3.8 (1.5–7.7)</td>
<td>212</td>
<td>6.6 (3.7–10.8)</td>
</tr>
<tr>
<td>CM third visit</td>
<td>175</td>
<td>3.4 (1.3–7.3)</td>
<td>172</td>
<td>1.2 (0.1–4.1)</td>
<td>194</td>
<td>2.1 (0.6–5.2)</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11428516">b</xref></sup></td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>&lt;0.0001</td>
</tr>
<tr>
<th align="center" colspan="7">Performance of Management Strategy for Detection of CIN3<sup><xref ref-type="table-fn" rid="table-fn5-0272989X11428516">d</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
</tr>
<tr>
<td>IC</td>
<td>23</td>
<td>43.5 (23.2–65.5)</td>
<td>35</td>
<td>51.4 (34.0–68.6)</td>
<td>42</td>
<td>57.1 (41.0–72.3)</td>
</tr>
<tr>
<td>HPV</td>
<td>10</td>
<td>80.0 (44.4–97.5)</td>
<td>11</td>
<td>63.6 (30.8–89.1)</td>
<td>19</td>
<td>52.6 (28.9–75.6)</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>27</td>
<td>40.7 (22.4–61.2)</td>
<td>28</td>
<td>53.6 (33.9–72.5)</td>
<td>37</td>
<td>45.95 (29.5–63.1)</td>
</tr>
<tr>
<td>CM first visit</td>
<td>27</td>
<td>18.5 (6.3–38.1)</td>
<td>28</td>
<td>39.3 (21.5–59.4)</td>
<td>37</td>
<td>32.4 (18.0–49.8)</td>
</tr>
<tr>
<td>CM second visit</td>
<td>21</td>
<td>14.3 (3.05–36.3)</td>
<td>13</td>
<td>15.4 (1.9–45.45)</td>
<td>18</td>
<td>27.8 (9.7–53.5)</td>
</tr>
<tr>
<td>CM third visit</td>
<td>17</td>
<td>17.65 (3.8–43.4)</td>
<td>11</td>
<td>18.2 (2.3–51.8)</td>
<td>11</td>
<td>0 (0.0–28.5)</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.1</td>
<td/>
<td>0.8</td>
<td/>
<td>0.6</td>
</tr>
<tr>
<th align="center" colspan="7">Sensitivity of Colposcopy for Detection of CIN3<sup><xref ref-type="table-fn" rid="table-fn6-0272989X11428516">e</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
</tr>
<tr>
<td>IC</td>
<td>23</td>
<td>43.5 (23.2–65.5)</td>
<td>35</td>
<td>51.4 (34.0–68.6)</td>
<td>42</td>
<td>57.1 (41.0–72.3)</td>
</tr>
<tr>
<td>HPV</td>
<td>10</td>
<td>80.0 (44.4–97.5)</td>
<td>10</td>
<td>70.0 (34.8–93.3)</td>
<td>17</td>
<td>58.8 (32.9–81.6)</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>12</td>
<td>91.7 (61.5–99.8)</td>
<td>19</td>
<td>78.95 (54.4–93.95)</td>
<td>24</td>
<td>70.8 (48.9–87.4)</td>
</tr>
<tr>
<td>CM first visit</td>
<td>6</td>
<td>83.3 (35.9–99.6)</td>
<td>15</td>
<td>73.3 (44.9–92.2)</td>
<td>17</td>
<td>70.6 (44.0–89.7)</td>
</tr>
<tr>
<td>CM second visit</td>
<td>3</td>
<td>100.0 (29.2–100.0)</td>
<td>2</td>
<td>100.0 (15.8–100.0)</td>
<td>6</td>
<td>83.3 (35.9–99.6)</td>
</tr>
<tr>
<td>CM third visit</td>
<td>3</td>
<td>100.0 (29.2–100.0)</td>
<td>2</td>
<td>100.0 (15.8–100.0)</td>
<td>1</td>
<td>0 (0–97.5)</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.008</td>
<td/>
<td>0.1</td>
<td/>
<td>0.5</td>
</tr>
<tr>
<th align="center" colspan="7">Positive Predictive Value of Colposcopy for Detection of CIN3<sup><xref ref-type="table-fn" rid="table-fn7-0272989X11428516">f</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
</tr>
<tr>
<td>IC</td>
<td>27</td>
<td>37.0 (19.4–57.6)</td>
<td>39</td>
<td>46.2 (30.1–62.8)</td>
<td>43</td>
<td>55.8 (39.9–70.9)</td>
</tr>
<tr>
<td>HPV</td>
<td>13</td>
<td>61.5 (31.6–86.1)</td>
<td>11</td>
<td>63.6 (30.8–89.1)</td>
<td>14</td>
<td>71.4 (41.9–91.6)</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>14</td>
<td>78.6 (49.2–95.3)</td>
<td>22</td>
<td>68.2 (45.1–86.1)</td>
<td>28</td>
<td>60.7 (40.6–78.5)</td>
</tr>
<tr>
<td>CM first visit</td>
<td>8</td>
<td>62.5 (24.5–91.5)</td>
<td>18</td>
<td>61.1 (35.75–82.7)</td>
<td>17</td>
<td>70.6 (44.0–89.7)</td>
</tr>
<tr>
<td>CM second visit</td>
<td>3</td>
<td>100 (29.2–100)</td>
<td>2</td>
<td>100 (15.8–100)</td>
<td>9</td>
<td>55.6 (21.2–86.3)</td>
</tr>
<tr>
<td>CM third visit</td>
<td>3</td>
<td>100 (29.2–100)</td>
<td>2</td>
<td>100 (15.8–100)</td>
<td>2</td>
<td>0 (0.0–84.2)</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.03</td>
<td/>
<td>0.2</td>
<td/>
<td>0.6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X11428516">
<p>Note: We excluded 2 (IC), 1 (HPV), and 1 (CM) cases of cancer detected at enrollment, although there was 1 cancer case included in the oldest tertile of the CM arm that was not detected until 18 months; this was a major failure of the arm. We report exact binomial confidence intervals. IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN3 = cervical intraepithelial neoplasia grade 3.</p>
</fn>
<fn id="table-fn2-0272989X11428516">
<label>a.</label>
<p><italic>P</italic> values from Fisher exact test for comparison of age tertiles within each study arm were not significant.</p>
</fn>
<fn id="table-fn3-0272989X11428516">
<label>b.</label>
<p><italic>P</italic> values from Fisher exact test for comparison between study arms. The CM arm (overall), as opposed to by visit, was compared to other arms. A Tukey-type multiple comparison test for proportions demonstrated that associations found for colposcopic referrals were significantly different between all 3 study arms, and sensitivity of colposcopy and positive predictive value were significantly different between the IC and CM arms in the youngest age tertile.</p>
</fn>
<fn id="table-fn4-0272989X11428516">
<label>c.</label>
<p>Percentage referred is out of the total number of women in the arm, regardless of missed visits. For IC and HPV referrals, only enrollment visit referrals are considered. For CM referrals, the enrollment, 6-month, and 12-month visit referrals are considered. We present results for the CM arm overall and by visit; the number of women in the arm decreases by visit as we censor women with HSIL+ and/or colposcopy at previous visits. For HPV referrals, missing results were defaulted as positive and referred to colposcopy.</p>
</fn>
<fn id="table-fn5-0272989X11428516">
<label>d.</label>
<p>“Performance of management strategy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visit in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN3 and thus conveys the combined sensitivity of the triage test (in the case of the HPV and CM arms) and clinical center colposcopy at identifying women with CIN3. For the CM arm, we present results overall and by visit; the number of CIN3 cases decreases by visit as we censor women with HSIL+ and/or colposcopy at previous visits.</p>
</fn>
<fn id="table-fn6-0272989X11428516">
<label>e.</label>
<p>“Sensitivity of colposcopy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, and 12-month visits in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN3 who were referred to colposcopy; this measure assesses the performance of colposcopy within an arm and does not account for how women got to colposcopy. For the CM arm, we present results overall and by visit; the number of CIN3 cases by visit represents the number referred due to HSIL+ at that visit.</p>
</fn>
<fn id="table-fn7-0272989X11428516">
<label>f.</label>
<p>“Positive predictive value of colposcopy for detection of CIN3” is defined as the probability of having a worst 2-year QC pathology group diagnosis of CIN3 among women who received a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visits in the CM arm).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Although prevalence of CIN3 increased slightly with age but did not vary significantly between study arms or age tertiles, it was highest in the HPV arm and lowest in the CM arm, with the difference perhaps due to the lead time detection of small prevalent lesions in the HPV arm that would have otherwise regressed.<sup><xref ref-type="fn" rid="fn3-0272989X11428516">c</xref></sup> We note the relatively higher CIN3 prevalence among women in the oldest tertile of the HPV arm (22.1%) compared with the other arms and age tertiles (~13%–16%), which we attribute in part to random error as a result of small sample size of the HPV arm (which closed early). As expected, colposcopic referrals were significantly different between all study arms across all age tertiles (<italic>P</italic> &lt; 0.0001), with the lowest percentage of referrals in the CM arm. While performance of management strategy for detection of CIN3 did not vary significantly between study arms or age tertiles, sensitivity of colposcopy was higher in the CM and HPV arms than in the IC arm, especially in women in the youngest tertile of age (<italic>P</italic> = 0.008). We hypothesize that the lower sensitivity in the IC arm may in part be due to colposcopists’ perception of lower risk among women who were automatically referred at enrollment as opposed to those referred several weeks later for abnormal triage test results (as in the HPV and CM arms). There was a significant association between study arm and positive predictive value of colposcopy in the youngest tertile (<italic>P</italic> = 0.03).</p>
</sec>
<sec id="section7-0272989X11428516">
<title>Costs</title>
<p>Costs are displayed in <xref ref-type="table" rid="table2-0272989X11428516">Table 2</xref>. We considered only direct medical costs that would be accrued to detect CIN3 using each management strategy in a clinical setting and ignored costs that would have accrued due to protocol-driven follow-up. We used Medicare reimbursement rates to estimate costs.<sup><xref ref-type="bibr" rid="bibr28-0272989X11428516">28</xref>,<xref ref-type="bibr" rid="bibr29-0272989X11428516">29</xref></sup></p>
<table-wrap id="table2-0272989X11428516" position="float">
<label>Table 2</label>
<caption>
<p>Direct Medical Costs</p>
</caption>
<graphic alternate-form-of="table2-0272989X11428516" xlink:href="10.1177_0272989X11428516-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Intervention</th>
<th align="center">Cost (2010 US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Cytology</td>
</tr>
<tr>
<td> Liquid-based Pap smear</td>
<td>29.02</td>
</tr>
<tr>
<td> Office visit</td>
<td>65.82</td>
</tr>
<tr>
<td> Physician review (for HSIL+ results)<sup><xref ref-type="table-fn" rid="table-fn9-0272989X11428516">a</xref></sup></td>
<td>15.13</td>
</tr>
<tr>
<td>Human papillomavirus test</td>
<td>28.72</td>
</tr>
<tr>
<td>Colposcopy (no biopsy + office visit)</td>
<td>170.69</td>
</tr>
<tr>
<td>Colposcopy (with biopsy + office visit)</td>
<td>203.78</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0272989X11428516">
<p>Note: From the 2010 clinical diagnostic laboratory fee schedule<sup><xref ref-type="bibr" rid="bibr28-0272989X11428516">28</xref></sup> and 2010 physician fee schedule.<sup><xref ref-type="bibr" rid="bibr29-0272989X11428516">29</xref></sup> HSIL = high-grade squamous intraepithelial lesion.</p>
</fn>
<fn id="table-fn9-0272989X11428516">
<label>a.</label>
<p>While cytology specimens are typically evaluated by a cytotechnologist, with results of ASCUS+ requiring review by a pathologist in a clinical setting, we conservatively assumed that only results of HSIL+ would be subject to pathologist review. This assumption should bias results in favor of CM by lowering costs.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0272989X11428516">
<title>Model assumptions</title>
<p>We made the following assumptions: 1) only clinical center colposcopy results from the enrollment visit were considered in the IC and HPV arms, and those from the enrollment, 6-month, and 12-month visits were considered in the CM arm; 2) women were censored from the model and could not accrue further costs or case detection after their initial clinical center colposcopy; 3) HPV DNA testing in the HPV arm was assumed to be reflex testing of liquid-based cytological samples from the referral visit and thus did not require an additional office visit; 4) women with missing HPV DNA test results were sent to colposcopy, as in the study; 5) testing positive in the CM arm was calculated separately for the enrollment, 6-month, and 12-month visits, conditional on participation and testing &lt;HSIL at previous visits; and 6) women in the CM arm who underwent the protocol modification were censored from the analysis thereafter.</p>
</sec>
<sec id="section9-0272989X11428516">
<title>Analysis</title>
<p>First, we conducted a cost-effectiveness analysis of age-based management of women with LSIL cytology results using unadjusted ALTS data (i.e., all probabilities in the model were derived from ALTS data on corresponding study arm and age tertile) (Step 1). In a second step, we adjusted for potential lead time bias in CIN3 detection and random error by using the same prevalence distribution of model health states for each study arm (Step 2a) and independently adjusted for ascertainment bias by informing colposcopic performance in a subgroup of the IC arm with data from a clinically comparable subgroup of the HPV arm (Step 2b). Finally, we adjusted for both lead time bias/random error and ascertainment bias simultaneously (Step 3).</p>
<p>To arrive at a prevalence distribution of model health states for each age tertile (Step 2a), we calculated a weighted average of the prevalence of each state (i.e., normal, CIN1, CIN2, CIN3) across all 3 arms. This distribution should allow us to reflect age trends in the prevalence of health states but will not favor one management strategy over another in cost-effectiveness analysis as the result of there being more cases of CIN3 detected in a particular arm over the course of the study.</p>
<p>To adjust for ascertainment bias among colposcopists (Step 2b), we estimated the extent to which greater colposcopic sensitivity in the HPV and CM arms was due to the clinical profile of women referred to colposcopy versus different management resulting from provider knowledge of the study arm. Published literature suggests that colposcopy is more sensitive to detect CIN2+ among women with an HSIL+ cytology result than in women with &lt;HSIL on cytology due to the correlation between HSIL+ on cytology and size of a lesion.<sup><xref ref-type="bibr" rid="bibr30-0272989X11428516">30</xref>,<xref ref-type="bibr" rid="bibr31-0272989X11428516">31</xref></sup> Data from ALTS suggest that HPV16 may cause more visual abnormalities than other HPV types, even after controlling for histological diagnosis.<sup><xref ref-type="bibr" rid="bibr32-0272989X11428516">32</xref></sup> We thus restricted CIN3 cases in each arm to those that were HC2+ (at enrollment in the IC and HPV arms and at the visit of referral to colposcopy in the CM arm)<sup><xref ref-type="fn" rid="fn4-0272989X11428516">d</xref></sup> and stratified these cases based on cytology result at enrollment (&lt;HSIL v. HSIL+). In the CM arm, clinical center colposcopy results were only available for women with HSIL+ (<xref ref-type="table" rid="table3-0272989X11428516">Table 3</xref>). While sensitivity of colposcopy to detect CIN3 was uniformly high across arms among women with HC2+ and HSIL+ at enrollment (all ages: Fisher exact, <italic>P</italic> = 0.7), sensitivity was lower in the IC arm relative to the HPV arm among women with HC2+ and &lt;HSIL (all ages: Fisher exact, <italic>P</italic> = 0.02). We explored how management of these women (CIN3, HC2+, &lt;HSIL) may have differed between the IC and HPV arms but were unable to determine a mechanism for differences in colposcopic performance based on examination of provider type, number of biopsies taken,<sup><xref ref-type="bibr" rid="bibr33-0272989X11428516">33</xref></sup> and severity of clinical center colposcopic impressions (<xref ref-type="table" rid="table7-0272989X11428516">Appendix Tables 3</xref>–<xref ref-type="table" rid="table9-0272989X11428516">5</xref>).</p>
<table-wrap id="table3-0272989X11428516" position="float">
<label>Table 3</label>
<caption>
<p>Performance of Colposcopy by Study Arm, Enrollment Cytology, and Age Tertile</p>
</caption>
<graphic alternate-form-of="table3-0272989X11428516" xlink:href="10.1177_0272989X11428516-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">&lt;21 Years</th>
<th align="center" colspan="2">21–24 Years</th>
<th align="center" colspan="2">25+ Years</th>
<th/>
</tr>
<tr>
<th align="center" colspan="8">Sensitivity of Colposcopy for Detection of CIN3, Given HSIL+ and HC2+<sup><xref ref-type="table-fn" rid="table-fn11-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn12-0272989X11428516">b</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>8</td>
<td>100.0 (63.1–100.0)</td>
<td>10</td>
<td>70.0 (34.8–93.3)</td>
<td>16</td>
<td>87.5 (61.7–98.4)</td>
<td>0.2</td>
</tr>
<tr>
<td>HPV</td>
<td>1</td>
<td>100.0 (2.5–100.0)</td>
<td>2</td>
<td>100.0 (15.8–100.0)</td>
<td>6</td>
<td>83.3 (35.9–99.6)</td>
<td>1.0</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>12</td>
<td>91.7 (61.5–99.8)</td>
<td>19</td>
<td>78.9 (54.4–93.9)</td>
<td>24</td>
<td>70.8 (48.9–87.4)</td>
<td>0.4</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn13-0272989X11428516">c</xref></sup></td>
<td/>
<td>1.0</td>
<td/>
<td>0.8</td>
<td/>
<td>0.5</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Sensitivity of Colposcopy for Detection of CIN3, Given &lt;HSIL and HC2+ at Enrollment<sup><xref ref-type="table-fn" rid="table-fn11-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn12-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>15</td>
<td>13.3 (1.7–40.4)</td>
<td>22</td>
<td>45.5 (24.4–67.8)</td>
<td>23</td>
<td>34.8 (16.4–57.3)</td>
<td>0.1</td>
</tr>
<tr>
<td>HPV</td>
<td>9</td>
<td>77.8 (40.0–97.2)</td>
<td>8</td>
<td>62.5 (24.5–91.5)</td>
<td>11</td>
<td>45.5 (16.7–76.6)</td>
<td>0.3</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn13-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.003</td>
<td/>
<td>0.7</td>
<td/>
<td>0.7</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn14-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, IC arm)</td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>0.3</td>
<td/>
<td>0.001</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn14-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, HPV arm)</td>
<td/>
<td>1.0</td>
<td/>
<td>1.0</td>
<td/>
<td>0.3</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Positive Predictive Value of Colposcopy for Detection of CIN3, Given HSIL+ and HC2+<sup><xref ref-type="table-fn" rid="table-fn11-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn12-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>13</td>
<td>61.5 (31.6–86.1)</td>
<td>14</td>
<td>50.0 (23.0–77.0)</td>
<td>21</td>
<td>66.7 (43.0–85.4)</td>
<td>0.7</td>
</tr>
<tr>
<td>HPV</td>
<td>3</td>
<td>33.3 (0.8–90.6)</td>
<td>5</td>
<td>40.0 (5.3–85.3)</td>
<td>7</td>
<td>71.4 (29.0–96.3)</td>
<td>0.5</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>14</td>
<td>78.6 (49.2–95.3)</td>
<td>22</td>
<td>68.2 (45.1–86.1)</td>
<td>28</td>
<td>60.7 (40.6–78.5)</td>
<td>0.5</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn13-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.2</td>
<td/>
<td>0.4</td>
<td/>
<td>0.9</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Positive Predictive Value of Colposcopy for Detection of CIN3, Given &lt;HSIL and HC2+ at Enrollment<sup><xref ref-type="table-fn" rid="table-fn11-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn12-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>14</td>
<td>14.3 (1.8–42.8)</td>
<td>22</td>
<td>45.5 (24.4–67.8)</td>
<td>20</td>
<td>40.0 (19.1–63.9)</td>
<td>0.13</td>
</tr>
<tr>
<td>HPV</td>
<td>10</td>
<td>70.0 (34.8–93.3)</td>
<td>6</td>
<td>83.3 (35.9–99.6)</td>
<td>7</td>
<td>71.4 (29.0–96.3)</td>
<td>1.0</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn13-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.01</td>
<td/>
<td>0.2</td>
<td/>
<td>0.2</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn14-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, IC arm)</td>
<td/>
<td>0.02</td>
<td/>
<td>1.0</td>
<td/>
<td>0.1</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn14-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, HPV arm)</td>
<td/>
<td>0.5</td>
<td/>
<td>0.2</td>
<td/>
<td>1.0</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0272989X11428516">
<p>Note: Colposcopic performance in the IC and HPV arms is evaluated at the enrollment visit and in the CM arm is evaluated at the enrollment, 6-month, and 12-month visits combined. We report exact binomial confidence intervals. HSIL+ = high-grade squamous intraepithelial lesion on cytology; &lt;HSIL = less than high-grade squamous intraepithelial lesion on cytology (i.e., normal, ASCUS, ASC-H, LSIL); CIN3 = cervical intraepithelial neoplasia grade 3; HC2+ = Hybrid Capture 2 positive or missing at enrollment in the IC and HPV arms (<italic>n</italic> = 3 missing in IC arm; <italic>n</italic> = 1 missing in HPV arm among women with CIN3) or at the visit of colposcopic referral for HSIL+ in the CM arm (<italic>n</italic> = 0 missing among women with CIN3).</p>
</fn>
<fn id="table-fn11-0272989X11428516">
<label>a.</label>
<p>“Sensitivity of colposcopy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, and 12-month visits in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN3 who were referred to colposcopy. For the CM arm, we present results overall and by visit; the number of CIN3 cases by visit represents the number referred due to HSIL+ at that visit. “Positive predictive value of colposcopy for detection of CIN3” is defined as the probability of having a worst 2-year QC pathology group diagnosis of CIN3 among women who received a histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visits in the CM arm) at a clinical center.</p>
</fn>
<fn id="table-fn12-0272989X11428516">
<label>b.</label>
<p>Fisher exact test, comparing across age tertiles.</p>
</fn>
<fn id="table-fn13-0272989X11428516">
<label>c.</label>
<p>Fisher exact test, comparing across study arms.</p>
</fn>
<fn id="table-fn14-0272989X11428516">
<label>d.</label>
<p>Fisher exact test, comparing across cytology interpretations (&lt;HSIL v. HSIL+) within a study arm.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among women with similar clinical profiles and seemingly smaller lesions (CIN3, HC2+, &lt;HSIL), we adjusted colposcopic performance in our model as follows (Step 2b). In the IC arm, we stratified women with CIN3 in the model based on whether they were HC2– or HC2+. Among the few women who were HC2– (youngest tertile: <italic>n</italic> = 0; middle tertile: <italic>n</italic> = 3; oldest tertile: <italic>n</italic> = 3), we made no adjustment, as we had no better data to inform sensitivity of colposcopy in this subgroup. Among HC2+ women, we further stratified on whether they were HSIL+ and &lt;HSIL at enrollment. For those with HSIL+ on enrollment cytology, we made no adjustment, given the similarity in colposcopic performance between arms in this subgroup. For women with &lt;HSIL on enrollment cytology, we used colposcopic performance data from women with a comparable profile (HC2+, &lt;HSIL) in the HPV arm.</p>
</sec>
</sec>
</sec>
<sec id="section10-0272989X11428516" sec-type="results">
<title>Results</title>
<sec id="section11-0272989X11428516">
<title>Step 1: Unadjusted ALTS Data</title>
<p>Results from the unadjusted analysis are presented in <xref ref-type="table" rid="table4-0272989X11428516">Table 4</xref>. One repeat cytology visit (CM first visit) was the least costly and least effective strategy across age tertiles. HPV triage to colposcopy was the most effective strategy across tertiles and, contrary to expectations, consistently dominated other strategies. We explored the impact of 2 potential sources of bias that led to these counterintuitive cost-effectiveness results, variation in prevalence of CIN3 by arm and potential ascertainment bias at colposcopy, separately (Steps 2a and 2b) and together (Step 3).</p>
<table-wrap id="table4-0272989X11428516" position="float">
<label>Table 4</label>
<caption>
<p>Costs, Effectiveness, and Cost-Effectiveness of Each Management Strategy for Detection of CIN3 for Steps 1 to 3</p>
</caption>
<graphic alternate-form-of="table4-0272989X11428516" xlink:href="10.1177_0272989X11428516-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="12">Step 1: Unadjusted ALTS Data</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;21 Years</th>
<th align="center" colspan="4">21–24 Years</th>
<th align="center" colspan="4">≥25 Years</th>
</tr>
<tr>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>CM (first visit)</td>
<td>112.96</td>
<td>24.1</td>
<td>—</td>
<td>CM (first visit)</td>
<td>126.89</td>
<td>50.2</td>
<td>—</td>
<td>CM (first visit)</td>
<td>120.62</td>
<td>49.0</td>
<td>—</td>
</tr>
<tr>
<td>CM (second visit)</td>
<td>186.28</td>
<td>38.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>HPV</td>
<td>180.37</td>
<td>104.4</td>
<td>$990</td>
<td>HPV</td>
<td>176.98</td>
<td>116.3</td>
<td>$840</td>
</tr>
<tr>
<td>HPV</td>
<td>197.62</td>
<td>115.9</td>
<td>$920</td>
<td>IC</td>
<td>198.34</td>
<td>77.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>199.19</td>
<td>89.8</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>198.07</td>
<td>59.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>201.38</td>
<td>59.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>203.85</td>
<td>69.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM (third visit)</td>
<td>249.28</td>
<td>53.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>260.11</td>
<td>68.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>265.10</td>
<td>69.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="12">Step 2a: Adjustment for Variation in Prevalence of CIN3</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;21 Years</th>
<th align="center" colspan="4">21–24 Years</th>
<th align="center" colspan="4">≥25 Years</th>
</tr>
<tr>
<th align="left">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM (first visit)</td>
<td>113.12</td>
<td>25.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>128.33</td>
<td>56.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>121.75</td>
<td>53.2</td>
<td>—</td>
</tr>
<tr>
<td>CM (second visit)</td>
<td>186.52</td>
<td>39.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>HPV</td>
<td>179.92</td>
<td>90.7</td>
<td>$1490</td>
<td>HPV</td>
<td>174.20</td>
<td>86.3</td>
<td>$1580</td>
</tr>
<tr>
<td>HPV</td>
<td>194.67</td>
<td>107.8</td>
<td>$980</td>
<td>IC</td>
<td>197.12</td>
<td>73.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>198.35</td>
<td>93.7</td>
<td>$3260</td>
</tr>
<tr>
<td>IC</td>
<td>196.92</td>
<td>58.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>202.51</td>
<td>66.2</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>204.92</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM (third visit)</td>
<td>249.58</td>
<td>54.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>261.08</td>
<td>76.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>265.65</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="12">Step 2b: Adjustment for Ascertainment Bias (Inferior Performance in IC Arm)</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;21 Years</th>
<th align="center" colspan="4">21–24 Years</th>
<th align="center" colspan="4">≥25 Years</th>
</tr>
<tr>
<th align="left">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM (first visit)</td>
<td>112.96</td>
<td>24.1</td>
<td>—</td>
<td>CM (first visit)</td>
<td>126.89</td>
<td>50.2</td>
<td>—</td>
<td>CM (first visit)</td>
<td>120.62</td>
<td>49.0</td>
<td>—</td>
</tr>
<tr>
<td>CM (second visit)</td>
<td>186.28</td>
<td>38.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>HPV</td>
<td>180.37</td>
<td>104.4</td>
<td>$990</td>
<td>HPV</td>
<td>176.98</td>
<td>116.3</td>
<td>$840</td>
</tr>
<tr>
<td>HPV</td>
<td>197.62</td>
<td>115.9</td>
<td>$920</td>
<td>IC</td>
<td>198.48</td>
<td>93.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>195.73</td>
<td>99.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>198.46</td>
<td>116.4</td>
<td>$1680</td>
<td>CM (second visit)</td>
<td>201.38</td>
<td>59.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>203.85</td>
<td>69.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM (third visit)</td>
<td>249.28</td>
<td>53.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>260.11</td>
<td>68.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>265.10</td>
<td>69.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="12">Step 3: Simultaneous Adjustment for Variation in Prevalence of CIN3 and Ascertainment Bias</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;21 Years</th>
<th align="center" colspan="4">21–24 Years</th>
<th align="center" colspan="4">≥25 Years</th>
</tr>
<tr>
<th align="left">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn16-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn17-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn18-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM (first visit)</td>
<td>113.12</td>
<td>25.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>128.33</td>
<td>56.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>121.75</td>
<td>53.2</td>
<td>—</td>
</tr>
<tr>
<td>CM (second visit)</td>
<td>186.52</td>
<td>39.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>HPV</td>
<td>179.92</td>
<td>90.7</td>
<td>$1490</td>
<td>HPV</td>
<td>174.20</td>
<td>86.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>HPV</td>
<td>194.67</td>
<td>107.8</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>197.25</td>
<td>88.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.74</td>
<td>103.2</td>
<td>$1460</td>
</tr>
<tr>
<td>IC</td>
<td>197.30</td>
<td>115.3</td>
<td>$930</td>
<td>CM (second visit)</td>
<td>202.51</td>
<td>66.2</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>204.92</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM (third visit)</td>
<td>249.58</td>
<td>54.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>261.08</td>
<td>76.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>265.65</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn19-0272989X11428516">d</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn15-0272989X11428516">
<p>Note: Strategies are presented in order of increasing cost. ICER = incremental cost-effectiveness ratio; IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN3 = cervical intraepithelial neoplasia grade 3.</p>
</fn>
<fn id="table-fn16-0272989X11428516">
<label>a.</label>
<p>Costs per hypothetical woman in the model are reported in 2010 US dollars.</p>
</fn>
<fn id="table-fn17-0272989X11428516">
<label>b.</label>
<p>Effects are reported as cases of CIN3+ detected per 1000 women in the model.</p>
</fn>
<fn id="table-fn18-0272989X11428516">
<label>c.</label>
<p>ICERs are reported as the cost per case of CIN3+ detected ($/case detected).</p>
</fn>
<fn id="table-fn19-0272989X11428516">
<label>d.</label>
<p>Dominated strategy (i.e., was more costly and less effective than other strategies or had a higher ICER than more effective strategies).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0272989X11428516">
<title>Step 2a: Adjustment for Variation in Prevalence of CIN3</title>
<p>When we used the same prevalence distribution of health states across study arms, ICERs for HPV triage to colposcopy became relatively less attractive than in Step 1 (<xref ref-type="table" rid="table4-0272989X11428516">Table 4</xref>). Effectiveness of HPV triage decreased because prevalence of CIN3, which had been slightly higher in the HPV triage arm than the IC arm in all age tertiles (<xref ref-type="table" rid="table1-0272989X11428516">Table 1</xref>), declined. With fewer cases of CIN3 in the HPV arm, the cost per case detected increased. While HPV triage remained the most attractive strategy (i.e., most effective and had the lowest ICER) in women under 25 years, and had the lowest ICER among women 25 years and over, IC was the most effective strategy among women 25 years and over, yielding an ICER of $3260 per CIN3 detected compared to HPV testing.</p>
</sec>
<sec id="section13-0272989X11428516">
<title>Step 2b: Adjustment for Potential Ascertainment Bias among Colposcopists in the IC Arm</title>
<p>When we adjusted performance of colposcopy among women in the IC arm with CIN3 who were HC2+ with &lt;HSIL on enrollment cytology, IC became the most effective strategy in the youngest tertile, as the sensitivity of colposcopy improved. However, IC remained more costly and less effective than HPV triage in women over 21 years (<xref ref-type="table" rid="table4-0272989X11428516">Table 4</xref>). HPV triage remained the strategy with the lowest ICER in all age tertiles, as with unadjusted trial data.</p>
</sec>
<sec id="section14-0272989X11428516">
<title>Step 3: Simultaneous Adjustment for Variation in Prevalence of CIN3 and Ascertainment Bias</title>
<p>Compared to the unadjusted data, standardizing CIN3 prevalence and adjusting colposcopic performance in the IC arm resulted in IC becoming the most attractive strategy (i.e., most effective and lowest ICER) in women under 21 years and 25 years and over. HPV triage remained the most attractive strategy in women aged 21 to 24 years because of its superior effectiveness and low cost in this age group.</p>
</sec>
</sec>
<sec id="section15-0272989X11428516" sec-type="discussion">
<title>Discussion</title>
<p>Our analysis demonstrates that economic evaluation results based on RCT data may change following adjustment for random error and biases in study design. We used ALTS data to evaluate the cost-effectiveness of strategies for CIN3 detection in women referred to the study with LSIL cytology results to determine whether there might be a role for HPV triage to colposcopy at older ages when HPV prevalence declines. While the use of unadjusted ALTS data leads to the finding that HPV triage is the most effective strategy and has the lowest ICER in all age groups, adjustments for variation in the prevalence of CIN3 between arms and possible ascertainment bias by clinical center colposcopists suggest that there may not be a role for HPV triage among women with LSIL. Despite our efforts at adjustment, the small sample size in the HPV arm, due to early closure, limits our power to detect age trends and significant predictors of colposcopic sensitivity. It also limits our power to discern true differences in colposcopic performance between arms from differences due to statistical noise.</p>
<p>As an economic evaluation, our analysis is limited in scope and is not intended to inform policy. It was conducted from a payer perspective with a short time horizon that ends at colposcopy. We did not include costs of treatment and did not capture the long-term societal economic, health, or quality of life impacts associated with positive colposcopy/biopsy interpretations (such as adverse events and long-term sequelae associated with treatment) or missed precancers. Extending the time horizon is beyond the scope of the present analysis. We demonstrate the range of policy conclusions that can be drawn in economic analysis when RCT data are taken at “face value” versus when we adjust for potential biases in study design.</p>
<p>Our adjustment for variation in prevalence of CIN3 between arms was simple (Step 2a) and involved calculating a weighted average across arms. Theoretically, given a large sample and no difference in lead time between arms, prevalence of CIN3 should have been uniform across study arms. In women under 25 years, the adjustment had minimal impact, changing prevalence of CIN3 by only 1% to 2%. ICERs associated with HPV triage increased slightly, as the cost per case of CIN3 detected was spread over fewer cases. In women over 25 years, however, CIN3 prevalence fell by nearly 6% as the result of adjustment, making IC the most effective strategy.</p>
<p>Inferior performance of colposcopy among women in the IC arm relative to the HPV arm, even after controlling for HPV status and enrollment cytology results, was presumably due to ascertainment bias. We hypothesize that the immediacy of colposcopy in relation to the enrollment visit alerted colposcopists that women were assigned to the IC arm. Colposcopists may have perceived these women as having lower risk of precancer than those in the HPV and CM arms, who were referred to colposcopy based on abnormal test results. The apparent bias occurred primarily in women with small lesions (i.e., &lt;HSIL on enrollment cytology, younger women) and may have led to less effective targeting of biopsies by providers. Following adjustment of colposcopic performance in the IC arm (Step 2b), IC was the most effective strategy in the youngest tertile, although HPV triage was more effective and had a lower cost-effectiveness ratio in women over 21 years.</p>
<p>Simultaneous adjustment for variation in CIN3 prevalence and ascertainment bias (Step 3) suggested that IC was the most effective strategy to detect CIN3 and had the lowest cost per case of CIN3 detected among women with LSIL under 21 years or 25 years and older.</p>
<p>Although our adjustments to CIN3 prevalence were within the confidence intervals for each study arm, and might have been assessed in sensitivity analysis, we emphasize the importance of incorporating adjustments into baseline assumptions when the analyst is confident that random error or bias is present. As Rittenhouse notes, “[t]he baseline case takes on an aura of having a greater likelihood of being correct if for no other reason than it represents the assumptions that dominate any report of results.”<sup><xref ref-type="bibr" rid="bibr3-0272989X11428516">3</xref></sup> Given the weight of baseline assumptions in decision making, these (rather than sensitivity analyses) should reflect our best sense of clinical realities.<sup><xref ref-type="bibr" rid="bibr3-0272989X11428516">3</xref></sup></p>
<p>There are limitations associated with our adjustment of colposcopic sensitivity in the IC arm. We did not adjust for sensitivity among women with HC2+ and HSIL+ because there was little indication of ascertainment bias in this subgroup, as the IC arm performed comparably, if not better than, the CM arm in all age tertiles. In 21 to 24 year olds with HC2+ and HSIL+, colposcopy in the IC arm detected 70% of CIN3 cases that were referred, while 100% of referred CIN3 cases were detected in the HPV arm (<xref ref-type="table" rid="table3-0272989X11428516">Table 3</xref>). While this difference was not statistically significant, the magnitude was large enough to make HPV triage the most effective strategy in this age group. We also did not adjust performance of colposcopy among women with CIN3 in the IC arm who were HC2–, as there was no comparable subgroup in the HPV and CM arms. Excluding these few women (<italic>n</italic> = 3 in 21–24 year olds; <italic>n</italic> = 3 in 25 years and older) did not change the rank order of strategies.</p>
<p>Our method of adjustment assumes that colposcopy in the IC arm underperformed as a result of providers’ knowledge of group. We cannot rule out a scenario in which the HPV and CM arms overperformed as a result of review bias arising from providers’ knowledge of abnormal test results. While it is unlikely that colposcopists were aware of particular HC2 or cytology results from enrollment, the lag time between enrollment and the colposcopy visit was an indication of abnormal triage results. If the discrepancy in colposcopic sensitivity between arms is due to review bias rather than ascertainment bias, it would be more appropriate to inform sensitivity in the HPV arm with data from the IC arm instead of vice versa. An exploratory analysis in which we adjusted for both variation in CIN3 prevalence and review bias (by informing colposcopic sensitivity among &lt;HSIL women in the HPV arm with data from &lt;HSIL, HC2+ women in the IC arm) yielded a similar rank ordering of strategies as the model in Step 3 of the present analysis (Appendix <xref ref-type="table" rid="table6-0272989X11428516">Table 6</xref>). Although ICERs were relatively higher due to the lower effectiveness of IC under this method of adjustment, IC was the most effective strategy and had the lowest ICER in the youngest and oldest tertiles, while HPV triage had the lowest ICER in the middle tertile. It is possible that both review and ascertainment bias were at work in ALTS, but we cannot discern the relative magnitude of either bias. We believe that underperformance in the IC arm was more influential than overperformance in the HPV arm based on the surprisingly low sensitivity of IC in the trial.</p>
<p>In real-world clinical practice, availability (or lack) of triage test results may affect how colposcopy is done. The fact that ALTS data capture this tendency is not necessarily problematic from the standpoint of economic evaluation if sensitivity is influenced by triage test availability in clinical practice. However, if colposcopists in the trial behaved differently not only because they were aware of study arm or triage results but also because they were self-conscious about protocol-driven review of their evaluations, this is a type of Hawthorne effect and is problematic from the standpoint of economic evaluation.<sup><xref ref-type="bibr" rid="bibr34-0272989X11428516">34</xref></sup> It is not possible to distinguish real-world provider behavior from a Hawthorne effect using trial data.</p>
<p>The threshold of HC2 positivity at which HPV triage might be cost-effective in a population of women with LSIL cytology results is of great interest to policy makers. Unfortunately, due to the importance of colposcopic sensitivity in assessing cost-effectiveness, and the remaining uncertainty in this parameter in the IC and HPV arms despite our best efforts at adjustment, we are unable to address this issue with precision. We emphasize the need for data on colposcopic performance—how performance varies by provider type, the influence of procedural factors, and how colposcopists use information from triage tests in routine clinical practice—to inform comparative effectiveness studies and economic evaluations.</p>
<p>Rather than approaching ALTS data with the view that either 1) its limitations are acceptable and data should be taken at “face value” or 2) its limitations and biases are unacceptable and the data should be ignored for purposes of economic analysis, we sought a middle ground by adjusting for variation in prevalence of CIN3 and possible ascertainment bias using data from the trial itself. While there are more statistically rigorous ways to adjust for biases using Bayesian methods (e.g., the confidence profile method described by Eddy),<sup><xref ref-type="bibr" rid="bibr35-0272989X11428516">35</xref></sup> our goal was to present a method of adjustment that was straightforward and grounded in understanding of trial design, clinical presentation of disease, and test performance. Eddy himself laments that the complexity of his method hampers its use among many researchers who assess health technologies.<sup><xref ref-type="bibr" rid="bibr36-0272989X11428516">36</xref></sup></p>
<p>Adjustments for random error and potential bias may not always impact policy conclusions, and the present analysis does not invalidate previously published findings from ALTS. A re-analysis of women referred to ALTS with ASCUS revealed that even after adjusting for possible variation in CIN3 prevalence and ascertainment bias (<xref ref-type="table" rid="table11-0272989X11428516">Appendix Tables 7</xref>–<xref ref-type="table" rid="table13-0272989X11428516">9</xref>), HPV triage remained the strategy with the lowest ICER in all age quartiles and the most effective strategy in women over age 25 years (<xref ref-type="table" rid="table14-0272989X11428516">Appendix Table 10</xref>). This is in line with other cost-effectiveness studies (including one based on ALTS data) that have found HPV triage to be an attractive strategy for women with ASCUS.<sup><xref ref-type="bibr" rid="bibr18-0272989X11428516">18</xref>,<xref ref-type="bibr" rid="bibr19-0272989X11428516">19</xref></sup> When evidence of bias is not pronounced, or a strategy is robustly attractive even as influential parameters are varied, adjusting for potential bias may not alter policy conclusions. The decision analyst must examine RCT design when the results of economic evaluation are sensitive to reasonable variation in trial parameters. Even when the unavailability of individual-level data prevents thorough examination of mechanisms for bias, the analyst can attempt crude adjustments (with varying levels of conservatism) based on published figures from the RCT (Appendix). If the optimal strategies shift when using reasonably adjusted versus unadjusted data, the analyst will be aware that the foundation of the economic evaluation is tenuous.</p>
<p>We present our methods of adjustment to demonstrate the potential pitfalls of taking RCT data at face value without consideration of biases in study design. Random error and biases may be present even in well-designed RCTs, and our analysis reveals that these may not always be obvious or readily confirmed, even when individual-level trial data are available. We assert that decision analysts need to examine study design, available trial data, and cost-effectiveness results closely in order to detect evidence of potential bias. Even if bias cannot be confirmed, efforts should be made to adjust the data and assess the impact of potential bias on policy conclusions. Failure to adjust RCT data may yield counterintuitive results in economic evaluation.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-0272989X11428516">
<title>Appendix</title>
<table-wrap id="table5-0272989X11428516" position="float">
<label>Appendix</label>
<graphic alternate-form-of="table5-0272989X11428516" xlink:href="10.1177_0272989X11428516-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Abbreviation</th>
<th align="center">Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALTS</td>
<td>ASCUS/LSIL Triage Study</td>
</tr>
<tr>
<td>ASCUS</td>
<td>Atypical squamous cells of undetermined significance</td>
</tr>
<tr>
<td>CIN</td>
<td>Cervical intraepithelial neoplasia</td>
</tr>
<tr>
<td>CM</td>
<td>Conservative management</td>
</tr>
<tr>
<td>HC2</td>
<td>Hybrid Capture 2</td>
</tr>
<tr>
<td>HPV</td>
<td>Human papillomavirus</td>
</tr>
<tr>
<td>HSIL</td>
<td>High-grade squamous intraepithelial lesion</td>
</tr>
<tr>
<td>IC</td>
<td>Immediate colposcopy</td>
</tr>
<tr>
<td>LSIL</td>
<td>Low-grade intraepithelial lesion</td>
</tr>
<tr>
<td>QC</td>
<td>Quality control (pathology group)</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section16-0272989X11428516">
<title>Supplementary Results for Women Referred to ALTS with a Diagnosis of LSIL</title>
<table-wrap id="table6-0272989X11428516" position="float">
<label>Appendix Table 2</label>
<caption>
<p>Influential Parameters: Performance of Management Strategies and Prevalence of CIN2/3 by Study Arm and Age Tertile among Women with an LSIL Referral Diagnosis</p>
</caption>
<graphic alternate-form-of="table6-0272989X11428516" xlink:href="10.1177_0272989X11428516-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">&lt;21 Years</th>
<th align="center" colspan="2">21–24 Years</th>
<th align="center" colspan="2">25+ Years</th>
<th/>
</tr>
<tr>
<th align="center" colspan="8">Prevalence of CIN2/3</th>
</tr>
<tr>
<th/>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN2/3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN2/3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN2/3, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn22-0272989X11428516">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>169</td>
<td>27.2 (20.7–34.6)</td>
<td>233</td>
<td>30.0 (24.2–36.4)</td>
<td>267</td>
<td>27.7 (22.4–33.5)</td>
<td>0.8</td>
</tr>
<tr>
<td>HPV</td>
<td>69</td>
<td>27.5 (17.5–39.6)</td>
<td>67</td>
<td>26.9 (16.8–39.1)</td>
<td>86</td>
<td>31.4 (21.8–42.3)</td>
<td>0.8</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>207</td>
<td>19.8 (14.6–25.9)</td>
<td>219</td>
<td>19.6 (14.6–25.5)</td>
<td>245</td>
<td>24.1 (18.9–29.9)</td>
<td>0.4</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn23-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.2</td>
<td/>
<td>0.04</td>
<td/>
<td>0.4</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Performance of Management Strategy for Detection of CIN2/3<sup><xref ref-type="table-fn" rid="table-fn24-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN2/3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN2/3 Detected, % (95% CI)</th>
<th align="center">CIN2/3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN2/3 Detected, % (95% CI)</th>
<th align="center">CIN2/3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN2/3 Detected, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn22-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>46</td>
<td>43.5 (28.9–58.9)</td>
<td>70</td>
<td>48.6 (36.4–60.8)</td>
<td>74</td>
<td>51.4 (39.4–63.15)</td>
<td>0.7</td>
</tr>
<tr>
<td>HPV</td>
<td>19</td>
<td>57.9 (33.5–79.75)</td>
<td>18</td>
<td>55.6 (30.8–78.5)</td>
<td>27</td>
<td>48.15 (28.7–68.1)</td>
<td>0.8</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>41</td>
<td>31.7 (18.1–48.1)</td>
<td>43</td>
<td>46.5 (31.2–62.4)</td>
<td>59</td>
<td>45.8 (32.7–59.3)</td>
<td>0.3</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn23-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.2</td>
<td/>
<td>0.8</td>
<td/>
<td>0.8</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Sensitivity of Colposcopy for Detection of CIN2/3<sup><xref ref-type="table-fn" rid="table-fn25-0272989X11428516">d</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN2/3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN2/3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN2/3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN2/3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN2/3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN2/3 Referrals Detected, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn22-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>46</td>
<td>43.5 (28.9–58.9)</td>
<td>70</td>
<td>48.6 (36.4–60.8)</td>
<td>74</td>
<td>51.4 (39.4–63.15)</td>
<td>0.7</td>
</tr>
<tr>
<td>HPV</td>
<td>19</td>
<td>57.9 (33.5–79.75)</td>
<td>17</td>
<td>58.8 (32.9–81.6)</td>
<td>25</td>
<td>52.0 (31.3–72.2)</td>
<td>0.9</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>19</td>
<td>68.4 (43.4–87.4)</td>
<td>29</td>
<td>69.0 (49.2–84.7)</td>
<td>36</td>
<td>77.1 (59.9–89.6)</td>
<td>0.6</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn23-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.2</td>
<td/>
<td>0.2</td>
<td/>
<td>0.03</td>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Positive Predictive Value of Colposcopy for Detection of CIN2/3<sup><xref ref-type="table-fn" rid="table-fn26-0272989X11428516">e</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn22-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>27</td>
<td>74.1 (53.7–88.9)</td>
<td>39</td>
<td>87.2 (72.6–95.7)</td>
<td>43</td>
<td>88.4 (74.9–96.1)</td>
<td>0.3</td>
</tr>
<tr>
<td>HPV</td>
<td>13</td>
<td>84.6 (54.6–98.1)</td>
<td>11</td>
<td>90.9 (58.7–99.8)</td>
<td>14</td>
<td>92.9 (66.1–99.8)</td>
<td>0.8</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>14</td>
<td>92.9 (66.1–99.8)</td>
<td>22</td>
<td>90.9 (70.8–98.9)</td>
<td>28</td>
<td>92.9 (76.5–99.1)</td>
<td>1.0</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn23-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.4</td>
<td/>
<td>1.0</td>
<td/>
<td>0.9</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn21-0272989X11428516">
<p>Note: IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN2/3 = cervical intraepithelial neoplasia grade 3 (we excluded 2 [IC], 1 [HPV], and 1 [CM] cases of cancer detected at enrollment, although there was 1 cancer case included in the oldest tertile of the CM arm that was not detected until 18 months; this was a major failure of the arm). We report exact binomial confidence intervals.</p>
</fn>
<fn id="table-fn22-0272989X11428516">
<label>a.</label>
<p><italic>P</italic> values from Fisher exact test for comparison of age tertiles within each study arm.</p>
</fn>
<fn id="table-fn23-0272989X11428516">
<label>b.</label>
<p><italic>P</italic> values from Fisher exact test for comparison between study arms. The CM arm (overall) was compared to other arms. A Tukey-type multiple comparison test for proportions demonstrated that associations found for sensitivity of colposcopy in women ≥25 years were significantly different between the IC and CM arms, and prevalence of CIN2/3 in women 21 to 24 years was significantly different between the IC and CM arms.</p>
</fn>
<fn id="table-fn24-0272989X11428516">
<label>c.</label>
<p>“Performance of management strategy for detection of CIN2/3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visit in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN2/3 and thus conveys the combined sensitivity of the triage test (in the case of the HPV and CM arms) and clinical center colposcopy at identifying women with CIN2/3.</p>
</fn>
<fn id="table-fn25-0272989X11428516">
<label>d.</label>
<p>“Sensitivity of colposcopy for detection of CIN2/3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, and 12-month visits in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN2/3 who were referred to colposcopy; this measure assesses the performance of colposcopy within an arm and does not account for how women got to colposcopy.</p>
</fn>
<fn id="table-fn26-0272989X11428516">
<label>e.</label>
<p>“Positive predictive value of colposcopy for detection of CIN2/3” is defined as the probability of having a worst 2-year QC pathology group diagnosis of CIN2/3 among women who received a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visits in the CM arm).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table7-0272989X11428516" position="float">
<label>Appendix Table 3</label>
<caption>
<p>Sensitivity of Colposcopy for Detection of CIN3 by Study Arm and Colposcopic Provider in Women with &lt;HSIL and HC2+ at Enrollment (All Ages)</p>
</caption>
<graphic alternate-form-of="table7-0272989X11428516" xlink:href="10.1177_0272989X11428516-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">IC Arm</th>
<th align="center" colspan="2">HPV Arm</th>
<th/>
</tr>
<tr>
<th/>
<th align="center">Cases of CIN3 Receiving Colposcopy, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">Cases of CIN3 Receiving Colposcopy, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn28-0272989X11428516">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurse practitioner</td>
<td>19</td>
<td>36.8 (16.3–61.6)</td>
<td>5</td>
<td>80.0 (28.4–99.5)</td>
<td>0.14</td>
</tr>
<tr>
<td>General gynecologist</td>
<td>12</td>
<td>50.0 (21.1–78.9)</td>
<td>4</td>
<td>75.0 (19.4–99.4)</td>
<td>0.6</td>
</tr>
<tr>
<td>Gynecological oncology fellow</td>
<td>12</td>
<td>0.0 (0.0–26.5)</td>
<td>9</td>
<td>55.6 (21.2–86.3)</td>
<td>0.006</td>
</tr>
<tr>
<td>Gynecological oncologist</td>
<td>15</td>
<td>40.0 (16.3–67.7)</td>
<td>7</td>
<td>71.4 (29.0–96.3)</td>
<td>0.4</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn29-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.02</td>
<td/>
<td>0.9</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn27-0272989X11428516">
<p>Note: Women who did not participate in colposcopy at enrollment, or had missing colposcopy or biopsy results, are excluded. CIN3 = cervical intraepithelial neoplasia grade 3; &lt;HSIL = less than high-grade squamous intraepithelial lesion on cytology (i.e., normal, ASCUS, ASC-H, LSIL); HC2+ = Hybrid Capture 2 positive or missing at enrollment. Distribution of providers was not associated with study arm (Fisher exact, <italic>P</italic> = 0.5).</p>
</fn>
<fn id="table-fn28-0272989X11428516">
<label>a.</label>
<p>By Fisher exact test: IC arm versus HPV arm for provider type.</p>
</fn>
<fn id="table-fn29-0272989X11428516">
<label>b.</label>
<p>By Fisher exact test: provider types within study arm.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table8-0272989X11428516" position="float">
<label>Appendix Table 4</label>
<caption>
<p>Number of Enrollment Biopsies Taken among Women with an LSIL Referral Diagnosis and with &lt;HSIL, HC2+/Missing, and Worst 2-Year QC Pathology Diagnosis of CIN3 by Provider Type</p>
</caption>
<graphic alternate-form-of="table8-0272989X11428516" xlink:href="10.1177_0272989X11428516-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">IC Arm</th>
<th align="center" colspan="2">HPV Arm</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn31-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th align="center" colspan="5">Nurse Practitioners</th>
</tr>
<tr>
<th/>
<th align="center">Frequency</th>
<th/>
<th align="center">Frequency</th>
<th align="center">Fisher Exact (0–1 v. 2+): 1.0</th>
</tr>
<tr>
<th align="left">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Wilcoxon: 0.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>1</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td/>
</tr>
<tr>
<td>2</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td/>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Total</td>
<td>19</td>
<td>Total</td>
<td>5</td>
<td/>
</tr>
<tr>
<td>Mean</td>
<td>1.526</td>
<td>Mean</td>
<td>1.4</td>
<td/>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>Median</td>
<td>1</td>
<td/>
</tr>
<tr>
<th align="center" colspan="5">General Gynecologists</th>
</tr>
<tr>
<th/>
<th align="center">Frequency</th>
<th/>
<th align="center">Frequency</th>
<th align="center">Fisher Exact (0–1 v. 2+): 1.0</th>
</tr>
<tr>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Wilcoxon: 0.9</th>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>1</td>
<td>7</td>
<td>1</td>
<td>3</td>
<td/>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>Total</td>
<td>4</td>
<td/>
</tr>
<tr>
<td>Mean</td>
<td>1.25</td>
<td>Mean</td>
<td>1.75</td>
<td/>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>Median</td>
<td>1</td>
<td/>
</tr>
<tr>
<th align="center" colspan="5">Gynecological Oncology Fellows</th>
</tr>
<tr>
<th/>
<th align="center">Frequency</th>
<th/>
<th align="center">Frequency</th>
<th align="center">Fisher Exact (0–1 v. 2+): 1.0</th>
</tr>
<tr>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Wilcoxon: 0.9</th>
</tr>
<tr>
<td>0</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>1</td>
<td>5</td>
<td>1</td>
<td>5</td>
<td/>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td/>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Total</td>
<td>12</td>
<td>Total</td>
<td>9</td>
<td/>
</tr>
<tr>
<td>Mean</td>
<td>1.25</td>
<td>Mean</td>
<td>1.2222</td>
<td/>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>Median</td>
<td>1</td>
<td/>
</tr>
<tr>
<th align="center" colspan="5">Gynecological Oncologists</th>
</tr>
<tr>
<th/>
<th align="center">Frequency</th>
<th/>
<th align="center">Frequency</th>
<th align="center">Fisher Exact (0–1 v. 2+): 1.0</th>
</tr>
<tr>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Biopsies, <italic>n</italic></th>
<th/>
<th align="center">Wilcoxon: 0.4</th>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>1</td>
<td>13</td>
<td>1</td>
<td>6</td>
<td/>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td/>
</tr>
<tr>
<td>Total</td>
<td>15</td>
<td>Total</td>
<td>7</td>
<td/>
</tr>
<tr>
<td>Mean</td>
<td>1</td>
<td>Mean</td>
<td>1.2857</td>
<td/>
</tr>
<tr>
<td>Median</td>
<td>1</td>
<td>Median</td>
<td>1</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn30-0272989X11428516">
<p>Note: Women with missing information on providers, missing/inadequate colposcopy results, or no colposcopy results were excluded. Overall, for the IC arm: mean of 1.276, median of 1; for the HPV arm: mean of 1.36, median of 1 (Wilcoxon 2-sample exact, <italic>P</italic> = 1.0).</p>
</fn>
<fn id="table-fn31-0272989X11428516">
<label>a.</label>
<p><italic>P</italic> values are by Fisher exact test comparing 0 to 1 versus 2+ biopsies in the IC versus HPV arm or by Wilcoxon 2-sample test comparing distribution of number of biopsies in the IC versus HPV arm.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table9-0272989X11428516" position="float">
<label>Appendix Table 5</label>
<caption>
<p>Colposcopic Impression at Enrollment among Women with an LSIL Referral Diagnosis and a Worst 2-Year QC Pathology Diagnosis of CIN3, HC2+/Missing, and &lt;HSIL at Enrollment in IC and HPV Arms</p>
</caption>
<graphic alternate-form-of="table9-0272989X11428516" xlink:href="10.1177_0272989X11428516-table9.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="2">IC Arm<sup><xref ref-type="table-fn" rid="table-fn33-0272989X11428516">a</xref></sup></th>
<th align="center" colspan="2">HPV Arm<sup><xref ref-type="table-fn" rid="table-fn33-0272989X11428516">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;LGL</td>
<td>5</td>
<td>&lt;LGL</td>
<td>1</td>
</tr>
<tr>
<td>LGL+</td>
<td>54</td>
<td>LGL+</td>
<td>24</td>
</tr>
<tr>
<td>Total</td>
<td>59</td>
<td>Total</td>
<td>25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn32-0272989X11428516">
<p>Note: Among women with adequate data on colposcopic impression. QC = quality control; CIN3 = cervical intraepithelial neoplasia grade 3; HC2 = Hybrid Capture 2 test; HSIL = high-grade squamous intraepithelial lesion; IC = immediate colposcopy arm; HPV = HPV DNA triage arm; LGL = low-grade lesion; HGL = high-grade lesion.</p>
</fn>
<fn id="table-fn33-0272989X11428516">
<label>a.</label>
<p>Fisher exact, <italic>P</italic> = 0.7.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table10-0272989X11428516" position="float">
<label>Appendix Table 6</label>
<caption>
<p>Costs, Effectiveness, and Cost-Effectiveness of Each Management Strategy for Detection of CIN3, Simultaneously Adjusting for Variation in CIN3 Prevalence and Review Bias among Women with an LSIL Referral Diagnosis</p>
</caption>
<graphic alternate-form-of="table10-0272989X11428516" xlink:href="10.1177_0272989X11428516-table10.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="4">&lt;21 Years</th>
<th align="center" colspan="4">21–24 Years</th>
<th align="center" colspan="4">≥25 Years</th>
</tr>
<tr>
<th align="left">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn35-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn36-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn37-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn35-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn36-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn37-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn35-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn36-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn37-0272989X11428516">c</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>CM (first visit)</td>
<td>113.12</td>
<td>25.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>128.33</td>
<td>56.0</td>
<td>—</td>
<td>CM (first visit)</td>
<td>121.75</td>
<td>53.2</td>
<td>—</td>
</tr>
<tr>
<td>CM (second visit)</td>
<td>186.52</td>
<td>39.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
<td>HPV</td>
<td>179.76</td>
<td>73.1</td>
<td>$3010</td>
<td>HPV</td>
<td>178.01</td>
<td>76.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>HPV</td>
<td>194.13</td>
<td>29.7</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>197.12</td>
<td>73.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>198.35</td>
<td>93.7</td>
<td>$1890</td>
</tr>
<tr>
<td>IC</td>
<td>196.92</td>
<td>58.6</td>
<td>$2490</td>
<td>CM (second visit)</td>
<td>202.51</td>
<td>66.2</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
<td>CM (second visit)</td>
<td>204.92</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM (third visit)</td>
<td>249.58</td>
<td>54.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
<td>CM (third visit)</td>
<td>261.08</td>
<td>76.4</td>
<td>$24,640</td>
<td>CM (third visit)</td>
<td>265.65</td>
<td>75.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn38-0272989X11428516">d</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn34-0272989X11428516">
<p>Note: We adjusted for review bias, which might arise from provider awareness of abnormal test results, by informing colposcopic sensitivity among &lt;HSIL women in the HPV arm with data from &lt;HSIL, HC2+ women in the IC arm. Strategies are presented in order of increasing cost. ICER = incremental cost-effectiveness ratio; IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN3 = cervical intraepithelial neoplasia grade 3.</p>
</fn>
<fn id="table-fn35-0272989X11428516">
<label>a.</label>
<p>Costs per hypothetical woman in the model are reported in 2010 US dollars.</p>
</fn>
<fn id="table-fn36-0272989X11428516">
<label>b.</label>
<p>Effects are reported as cases of CIN3+ detected per 1000 women in the model.</p>
</fn>
<fn id="table-fn37-0272989X11428516">
<label>c.</label>
<p>ICERs are reported as the cost per case of CIN3+ detected ($/case detected).</p>
</fn>
<fn id="table-fn38-0272989X11428516">
<label>d.</label>
<p>Dominated strategy (i.e., was more costly and less effective than other strategies or had a higher ICER than more effective strategies).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-0272989X11428516">
<title>Supplementary Results for Women Referred to ALTS with a Diagnosis of ASCUS</title>
<p>We assessed the cost-effectiveness of triage strategies for women referred to ALTS with an ASCUS diagnosis in order to observe the effect of data adjustments for variation in CIN3 prevalence and potential ascertainment bias on this population.<sup><xref ref-type="fn" rid="fn1-0272989X11428516">a</xref></sup> We stratified women into age quartiles (&lt;22 years, 22–25 years, 26–33 years, and ≥34 years). We assessed the distribution of key trial parameters that determine the effectiveness and cost-effectiveness of management strategies by study arm and age quartile (Appendix <xref ref-type="table" rid="table7-0272989X11428516">Table 7</xref>).</p>
<p>As expected, the prevalence of CIN3 in ASCUS women was slightly lower than that in LSIL women (<xref ref-type="table" rid="table1-0272989X11428516">Table 1</xref>). In ASCUS women, there did not appear to be evidence of a lead time bias in the HPV or IC arms, as the prevalence of CIN3 was not consistently highest in any particular arm. There is apparent random fluctuation in CIN3 prevalence by study arm. Unlike LSIL women, in whom we found no evidence of increasing CIN3 prevalence with age, the prevalence of CIN3 in women with an ASCUS referral is significantly associated with age. Women ≥34 years have a significantly lower prevalence of CIN3 across study arms. There is a significant association between study arm and the proportion of women referred to colposcopy in all age quartiles (<italic>P</italic> &lt; 0.0001). In both the HPV and CM arms, there is a trend toward fewer colposcopic referrals as women age (HPV arm: <italic>P</italic> &lt; 0.0001; CM arm: <italic>P</italic> = 0.0001). In all but the youngest quartile, overall performance of management strategy was superior in the HPV arm but only significantly so in the oldest quartile (<italic>P</italic> = 0.006).</p>
<p>There was a significant or marginally significant association between study arm and sensitivity of colposcopy in all quartiles except for 26 to 33 year olds. In all but the oldest quartile, the sensitivity of colposcopy was highest in the CM arm, likely due to enhanced visualization of HSIL+. The low sensitivity of the CM arm (50.0%) relative to the HPV arm (85.7%) in the oldest quartile is likely due to the small number of CIN3 cases referred in the CM arm (<italic>n</italic> = 4) and is probably due to chance. In all but the oldest age quartile, the sensitivity of colposcopy is 10% to 20% higher in the HPV arm than in the IC arm. In the oldest quartile, sensitivity is 63% higher in the HPV arm than the IC arm (<italic>P</italic> = 0.02). There was a significant or marginally significant association between positive predictive value and study arm in women &lt;22 years old and women 26 to 33 years old, with positive predictive value being highest in the CM arm and lowest in the IC arm.</p>
<p>To further investigate the association between sensitivity of colposcopy to detect CIN3 and study arm, we stratified women who were HC2+ (or had missing HC2 results) at enrollment according to enrollment cytology (&lt;HSIL v. HSIL+). Results for all ages (Appendix <xref ref-type="table" rid="table8-0272989X11428516">Table 8</xref>) and by age quartile (Appendix <xref ref-type="table" rid="table9-0272989X11428516">Table 9</xref>) are shown below.</p>
<p>When we included women of all ages who were HC2+/HC2 missing and stratified according to cytology result, there was a marginally significant association between study arm and sensitivity of colposcopy among women with &lt;HSIL (<italic>P</italic> = 0.06) but not among women with HSIL+ (<italic>P</italic> = 0.11) (Appendix <xref ref-type="table" rid="table8-0272989X11428516">Table 8</xref>). Colposcopic sensitivity was highest in the HPV arm, even among women with a comparable clinical profile. There was also a marginally significant association between positive predictive value of colposcopy and study arm for women with enrollment cytology &lt;HSIL (<italic>P</italic> = 0.07). Positive predictive value was significantly different for &lt;HSIL versus HSIL+ within the IC arm (<italic>P</italic> = 0.02) but not within the HPV arm (<italic>P</italic> = 0.12).</p>
<p>When we stratified by age quartile (Appendix <xref ref-type="table" rid="table9-0272989X11428516">Table 9</xref>), the association between study arm and sensitivity of colposcopy among women with HSIL+ was nonsignificant, although sensitivity of colposcopy was always highest in the HPV arm. Among women with &lt;HSIL who were &lt;22 years old, sensitivity was significantly higher in the HPV arm than the IC arm. There was no association between study arm and positive predictive value of colposcopy, regardless of age quartile or cytology result (Appendix <xref ref-type="table" rid="table9-0272989X11428516">Table 9</xref>).</p>
<p>As when we analyzed women with an LSIL referral, we first present cost-effectiveness results for unadjusted trial data (Step 1).<sup><xref ref-type="fn" rid="fn2-0272989X11428516">b</xref></sup> We then present cost-effectiveness results after trial data were adjusted for variation in CIN3 prevalence due to potential lead time bias and/or random error (Step 2a), after data were adjusted for potential ascertainment bias in the IC arm (Step 2b) and after data were simultaneously adjusted for variation in CIN3 prevalence and ascertainment bias in the IC arm (Step 3) (Appendix <xref ref-type="table" rid="table10-0272989X11428516">Table 10</xref>).</p>
<p>A detailed description of data adjustments is in the main article reporting on the LSIL analysis, but we summarize briefly here. To adjust for variation in CIN3 prevalence (Step 2a), we calculated a weighted average of the prevalence of each state (i.e., normal, CIN1, CIN2, CIN3) across all 3 arms. To adjust for potential ascertainment bias in the IC arm (Step 2b), we stratified women with CIN3 in the model based on whether they were HC2– or HC2+ at enrollment. Among the few women who were HC2– (&lt;22: <italic>n</italic> = 2; 22–25: <italic>n</italic> = 4; 26–33: <italic>n</italic> = 2; ≥34: <italic>n</italic> = 4), we made no adjustment, as we had no better data to inform sensitivity of colposcopy in this subgroup. Among HC2+ and HC2 missing women, we further stratified on whether they were HSIL+ and &lt;HSIL at enrollment. For those who had HSIL+ on enrollment cytology, we made no adjustment, given the similarity in colposcopic performance between arms in this subgroup. For women who were &lt;HSIL on enrollment cytology, we used colposcopic performance data from women with a comparable profile (HC2+/HC2 missing, &lt;HSIL) in the HPV arm. To simultaneously adjust for variation in CIN3 prevalence and potential ascertainment bias in the IC arm, we performed both adjustments simultaneously (Step 3).</p>
<p>When we used unadjusted trial data (Step 1), HPV triage had the lowest ICER across age quartiles, and the ratio became more attractive as age increased. In women &lt;22 years, 3 repeat cytology visits were most effective but also the most costly strategy. Among women 22 to 25 years, IC was the most effective strategy but cost $4720 per CIN3 detected, relative to the $860 per CIN3 detected by the HPV arm. In women over 25 years, HPV triage was the most effective strategy and had the lowest ICER.</p>
<p>When we adjusted for variation in CIN3 prevalence (Step 2a), the ranking of strategies generally remained the same across quartiles, with HPV triage remaining the strategy with the lowest ICER. The only change in ranking occurred in women 22 to 25 years, with HPV replacing IC as the most effective strategy as well as the one with the lowest ratio. This occurred due to the relatively higher prevalence of CIN3 in the IC arm in the unadjusted data.</p>
<p>When we adjusted for potential ascertainment bias in the IC arm by substituting colpsocopic sensitivity from the HPV arm for women &lt;HSIL (Step 2b), HPV continued to be the strategy with the lowest ICER in all age quartiles. The ranking of strategies was similar to unadjusted data, except for the fact that IC became the most effective strategy in women ≥34 years.</p>
<p>When we simultaneously adjusted for variation in CIN3 prevalence and potential ascertainment bias in the IC arm (Step 3), the ranking of strategies was the same as with unadjusted data; HPV triage was consistently the strategy with the lowest ICER.</p>
<table-wrap id="table11-0272989X11428516" position="float">
<label>Appendix Table 7</label>
<caption>
<p>Influential Parameters by Study Arm and Age Quartile among Women with an ASCUS Referral Diagnosis</p>
</caption>
<graphic alternate-form-of="table11-0272989X11428516" xlink:href="10.1177_0272989X11428516-table11.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">&lt;22 Years</th>
<th align="center" colspan="2">22–25 Years</th>
<th align="center" colspan="2">26–33 years</th>
<th align="center" colspan="2">34+ Years</th>
<th/>
</tr>
<tr>
<th align="center" colspan="10">Prevalence of CIN3</th>
</tr>
<tr>
<th/>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">CIN3, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn40-0272989X11428516">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>307</td>
<td>7.8 (5.1–11.4)</td>
<td>286</td>
<td>14.0 (10.2–18.6)</td>
<td>273</td>
<td>7.3 (4.5–11.1)</td>
<td>289</td>
<td>4.5 (2.4–7.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>HPV</td>
<td>289</td>
<td>12.1 (8.6–16.4)</td>
<td>273</td>
<td>11.0 (7.5–15.3)</td>
<td>296</td>
<td>9.8 (6.7–13.8)</td>
<td>296</td>
<td>2.4 (1.0–4.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>264</td>
<td>12.5 (8.8–17.1)</td>
<td>263</td>
<td>12.2 (8.5–16.7)</td>
<td>333</td>
<td>9.0 (6.2–12.6)</td>
<td>283</td>
<td>4.2 (2.2–7.3)</td>
<td>0.001</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn41-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.1</td>
<td/>
<td>0.6</td>
<td/>
<td>0.6</td>
<td/>
<td>0.3</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Colposcopic Referrals<sup><xref ref-type="table-fn" rid="table-fn42-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center">Women in Arm, <italic>n</italic></th>
<th align="center">Referred to Colposcopy, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn40-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>307</td>
<td>100 (98.8–100)</td>
<td>286</td>
<td>100 (98.7–100)</td>
<td>273</td>
<td>100 (98.7–100)</td>
<td>289</td>
<td>100 (98.7–100)</td>
<td>NA</td>
</tr>
<tr>
<td>HPV</td>
<td>289</td>
<td>75.4 (70.1–80.3)</td>
<td>273</td>
<td>66.7 (60.7–72.2)</td>
<td>296</td>
<td>55.1 (49.2–60.8)</td>
<td>296</td>
<td>26.7 (21.7–32.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>264</td>
<td>15.5 (11.4–20.5)</td>
<td>263</td>
<td>13.3 (9.45–18.0)</td>
<td>333</td>
<td>11.1 (7.9–15.0)</td>
<td>283</td>
<td>4.6 (2.5–7.7)</td>
<td>0.0001</td>
</tr>
<tr>
<td>CM first visit</td>
<td>264</td>
<td>11.0 (7.5–15.4)</td>
<td>263</td>
<td>8.75 (5.6–12.8)</td>
<td>333</td>
<td>8.1 (5.4–11.6)</td>
<td>283</td>
<td>2.5 (1.0–5.0)</td>
<td/>
</tr>
<tr>
<td>CM second visit</td>
<td>232</td>
<td>3.9 (1.8–7.2)</td>
<td>240</td>
<td>1.7 (0.5–4.2)</td>
<td>303</td>
<td>2.3 (0.9–4.7)</td>
<td>272</td>
<td>1.8 (0.6–4.2)</td>
<td/>
</tr>
<tr>
<td>CM third visit</td>
<td>221</td>
<td>1.4 (0.3–3.9)</td>
<td>236</td>
<td>3.4 (1.5–6.6)</td>
<td>292</td>
<td>1.0 (0.2–3.0)</td>
<td>265</td>
<td>0.4 (0–2.1)</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn41-0272989X11428516">b</xref></sup></td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>&lt;0.0001</td>
<td/>
<td>&lt;0.0001</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Performance of Management Strategy for Detection of CIN3<sup><xref ref-type="table-fn" rid="table-fn25-0272989X11428516">d</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center">CIN3 Cases in Arm, <italic>n</italic></th>
<th align="center">CIN3 Detected, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn40-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>24</td>
<td>41.7 (22.1–63.4)</td>
<td>40</td>
<td>55.0 (38.5–70.7)</td>
<td>20</td>
<td>50.0 (27.2–72.8)</td>
<td>13</td>
<td>23.1 (5.0–53.8)</td>
<td>0.23</td>
</tr>
<tr>
<td>HPV</td>
<td>35</td>
<td>57.1 (39.4–73.7)</td>
<td>30</td>
<td>60.0 (40.6–77.3)</td>
<td>29</td>
<td>65.5 (45.7–82.1)</td>
<td>7</td>
<td>85.7 (42.1–99.6)</td>
<td>0.56</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>33</td>
<td>63.6 (45.1–79.6)</td>
<td>32</td>
<td>43.8 (26.4–62.3)</td>
<td>30</td>
<td>46.7 (28.3–65.7)</td>
<td>12</td>
<td>16.7 (2.1–48.4)</td>
<td>0.04</td>
</tr>
<tr>
<td>CM first visit</td>
<td>33</td>
<td>45.5 (28.1–63.65)</td>
<td>32</td>
<td>25.0 (11.5–43.4)</td>
<td>30</td>
<td>43.3 (25.5–62.6)</td>
<td>12</td>
<td>8.3 (0.2–38.5)</td>
<td/>
</tr>
<tr>
<td>CM second visit</td>
<td>17</td>
<td>23.5 (6.8–49.9)</td>
<td>23</td>
<td>0 (0–14.8)</td>
<td>14</td>
<td>7.1 (0.2–33.9)</td>
<td>9</td>
<td>0 (0–33.6)</td>
<td/>
</tr>
<tr>
<td>CM third visit</td>
<td>10</td>
<td>20.0 (2.5–55.6)</td>
<td>22</td>
<td>27.3 (10.7–50.2)</td>
<td>12</td>
<td>0 (0–26.5)</td>
<td>9</td>
<td>11.1 (0.3–48.25)</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn41-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.3</td>
<td/>
<td>0.45</td>
<td/>
<td>0.35</td>
<td/>
<td>0.006</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Sensitivity of Colposcopy for Detection of CIN3<sup>e</sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Referrals Detected, % (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn40-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>24</td>
<td>41.7 (22.1–63.4)</td>
<td>40</td>
<td>55.0 (38.5–70.7)</td>
<td>20</td>
<td>50.0 (27.2–72.8)</td>
<td>13</td>
<td>23.1 (5.0–53.8)</td>
<td>0.23</td>
</tr>
<tr>
<td>HPV</td>
<td>34</td>
<td>58.8 (40.7–75.4)</td>
<td>27</td>
<td>66.7 (46.0–83.5)</td>
<td>28</td>
<td>67.9 (47.65–84.1)</td>
<td>7</td>
<td>85.7 (42.1–99.6)</td>
<td>0.64</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>22</td>
<td>95.5 (77.2–99.5)</td>
<td>16</td>
<td>87.5 (61.7–98.45)</td>
<td>18</td>
<td>77.8 (52.4–93.6)</td>
<td>4</td>
<td>50.0 (6.8–93.2)</td>
<td>0.08</td>
</tr>
<tr>
<td>CM first visit</td>
<td>15</td>
<td>100 (78.2–100)</td>
<td>9</td>
<td>88.9 (51.8–99.7)</td>
<td>16</td>
<td>81.3 (54.4–96.0)</td>
<td>3</td>
<td>33.3 (0.8–90.6)</td>
<td/>
</tr>
<tr>
<td>CM second visit</td>
<td>5</td>
<td>80 (28.4–49.5)</td>
<td>1</td>
<td>0 (0–97.5)</td>
<td>1</td>
<td>100 (2.5–100)</td>
<td>0</td>
<td>NA</td>
<td/>
</tr>
<tr>
<td>CM third visit</td>
<td>2</td>
<td>100 (15.8–100)</td>
<td>6</td>
<td>100 (54.1–100)</td>
<td>1</td>
<td>0 (0–97.5)</td>
<td>1</td>
<td>100 (2.5–100)</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn41-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.0002</td>
<td/>
<td>0.06</td>
<td/>
<td>0.2</td>
<td/>
<td>0.03</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Positive Predictive Value of Colposcopy for Detection of CIN3<sup><xref ref-type="table-fn" rid="table-fn45-0272989X11428516">f</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn40-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>32</td>
<td>31.3 (16.1–50.0)</td>
<td>41</td>
<td>53.7 (37.4–69.3)</td>
<td>25</td>
<td>40.0 (21.1–61.3)</td>
<td>8</td>
<td>37.5 (8.5–75.5)</td>
<td>0.28</td>
</tr>
<tr>
<td>HPV</td>
<td>43</td>
<td>46.5 (31.2–62.35)</td>
<td>30</td>
<td>60.0 (40.6–77.3)</td>
<td>29</td>
<td>65.5 (45.7–82.1)</td>
<td>10</td>
<td>60.0 (26.2–87.8)</td>
<td>0.42</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>29</td>
<td>72.4 (52.8–87.3)</td>
<td>18</td>
<td>77.8 (52.4–93.6)</td>
<td>19</td>
<td>73.7 (48.8–90.9)</td>
<td>4</td>
<td>50.0 (6.8–93.2)</td>
<td>0.74</td>
</tr>
<tr>
<td>CM first visit</td>
<td>21</td>
<td>71.4 (47.8–88.7)</td>
<td>12</td>
<td>66.7 (34.9–90.1)</td>
<td>16</td>
<td>81.3 (54.4–96.0)</td>
<td>1</td>
<td>100 (2.5–100)</td>
<td/>
</tr>
<tr>
<td>CM second visit</td>
<td>6</td>
<td>66.7 (22.3–95.7)</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>33.3 (0.8–90.6)</td>
<td>2</td>
<td>0 (0–84.2)</td>
<td/>
</tr>
<tr>
<td>CM third visit</td>
<td>2</td>
<td>100 (15.8–100)</td>
<td>6</td>
<td>100 (54.1–100)</td>
<td>0</td>
<td>NA</td>
<td>1</td>
<td>100 (2.5–100)</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn41-0272989X11428516">b</xref></sup></td>
<td/>
<td>0.005</td>
<td/>
<td>0.2</td>
<td/>
<td>0.06</td>
<td/>
<td>0.85</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn39-0272989X11428516">
<p>Note: We excluded 1 (CM arm) case of cancer detected at enrollment in 22 to 25 year olds, although there was 1 cancer case included in women ≥34 years old (IC arm) that was detected at 12 months; this was a major failure of the arm. We report exact binomial confidence intervals. IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN3 = cervical intraepithelial neoplasia grade 3.</p>
</fn>
<fn id="table-fn40-0272989X11428516">
<label>a.</label>
<p><italic>P</italic> values from Fisher exact test for comparison of age quartiles within each study arm.</p>
</fn>
<fn id="table-fn41-0272989X11428516">
<label>b.</label>
<p><italic>P</italic> values from Fisher exact test for comparison between study arms. The CM arm (overall), as opposed to by visit, was compared to other arms.</p>
</fn>
<fn id="table-fn42-0272989X11428516">
<label>c.</label>
<p>Percentage referred is out of the total number of women in the arm, regardless of missed visits. For IC and HPV referrals, only enrollment visit referrals are considered. For CM referrals, the enrollment, 6-month, and 12-month visit referrals are considered. We present results for the CM arm overall and by visit; the number of women in the arm decreases by visit as we censor women with HSIL+ and/or colposcopy at previous visits. For HPV referrals, missing results were defaulted as positive and referred to colposcopy.</p>
</fn>
<fn id="table-fn43-0272989X11428516">
<label>d.</label>
<p>“Performance of management strategy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visit in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN3 and thus conveys the combined sensitivity of the triage test (in the case of the HPV and CM arms) and clinical center colposcopy at identifying women with CIN3. For the CM arm, we present results overall and by visit; the number of CIN3 cases decreases by visit as we censor women with HSIL+ and/or colposcopy at previous visits.</p>
</fn>
<fn id="table-fn44-0272989X11428516">
<label>e.</label>
<p>“Sensitivity of colposcopy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, and 12-month visits in the CM arm) among women in an arm who have a worst 2-year pathology group diagnosis of CIN3 who were referred to colposcopy; this measure assesses the performance of colposcopy within an arm and does not account for how women got to colposcopy. For the CM arm, we present results overall and by visit; the number of CIN3 cases by visit represents the number referred due to HSIL+ at that visit.</p>
</fn>
<fn id="table-fn45-0272989X11428516">
<label>f.</label>
<p>“Positive predictive value of colposcopy for detection of CIN3” is defined as the probability of having a worst 2-year QC pathology group diagnosis of CIN3 among women who received a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visits in the CM arm) at a clinical center.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table12-0272989X11428516" position="float">
<label>Appendix Table 8</label>
<caption>
<p>Colposcopic Performance by Study Arm and Enrollment Cytology among Women with an ASCUS Referral Diagnosis (All Ages)</p>
</caption>
<graphic alternate-form-of="table12-0272989X11428516" xlink:href="10.1177_0272989X11428516-table12.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">IC</th>
<th align="center" colspan="2">HPV</th>
<th align="center" colspan="2">CM</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn47-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th align="center" colspan="8">Sensitivity of Colposcopy, Given HC2+/Missing<sup><xref ref-type="table-fn" rid="table-fn48-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">CIN3 Referrals Detected, % (95% CI)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>HSIL+</td>
<td>34</td>
<td>70.6 (52.5–84.9)</td>
<td>31</td>
<td>90.3 (74.25–98.0)</td>
<td>60</td>
<td>85.0 (73.4–92.9)</td>
<td>0.11</td>
</tr>
<tr>
<td>&lt;HSIL</td>
<td>50</td>
<td>36.0 (22.9–50.8)</td>
<td>65</td>
<td>53.85 (41.0–66.3)</td>
<td/>
<td/>
<td>0.06</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn49-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.004</td>
<td/>
<td>0.0004</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<th align="center" colspan="8">Positive Predictive Value, Given HC2+/Missing<sup><xref ref-type="table-fn" rid="table-fn48-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies (CC CIN2+), <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies (CC CIN2+), <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies (CC CIN2+), <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn47-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<td>HSIL+</td>
<td>40</td>
<td>60.0 (43.3–75.1)</td>
<td>42</td>
<td>66.7 (50.5–80.4)</td>
<td>70</td>
<td>72.9 (60.9–82.8)</td>
<td>0.37</td>
</tr>
<tr>
<td>&lt;HSIL</td>
<td>54</td>
<td>33.3 (21.1–47.5)</td>
<td>70</td>
<td>50.0 (37.8–62.2)</td>
<td/>
<td/>
<td>0.07</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn49-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.02</td>
<td/>
<td>0.12</td>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn46-0272989X11428516">
<p>Note: Women with missing enrollment cytology were not included in this analysis. Colposcopic performance in the IC and HPV arms is evaluated at the enrollment visit and in the CM arm is evaluated at the enrollment, 6-month, and 12-month visits combined. We report exact binomial confidence intervals. We excluded 1 cancer case in the CM arm that was censored at enrollment but included 1 cancer case in the IC arm that was not detected until 12 months. HSIL+ = high-grade squamous intraepithelial lesion on cytology; &lt;HSIL = less than high-grade squamous intraepithelial lesion on cytology (i.e., normal, ASCUS, ASC-H, LSIL); CIN3 = cervical intraepithelial neoplasia grade 3; HC2+ = Hybrid Capture 2 positive or missing at enrollment in the IC and HPV arms or at the visit of colposcopic referral for HSIL+ in the CM arm.</p>
</fn>
<fn id="table-fn47-0272989X11428516">
<label>a.</label>
<p>Fisher exact test, comparing across study arms.</p>
</fn>
<fn id="table-fn48-0272989X11428516">
<label>b.</label>
<p>Sensitivity proportion of women with CIN3 (as determined by worst QC diagnosis throughout the study) who are referred to colposcopy and have a CC colposcopy diagnosis of CIN2 or higher (at enrollment in the case of the IC and HPV arms and at 0, 6, or 12 months in the CM arm). Positive predictive value is the proportion of women with a CC colposcopy diagnosis of CIN2 or higher who had CIN3.</p>
</fn>
<fn id="table-fn49-0272989X11428516">
<label>c.</label>
<p>Fisher exact test, comparing across cytology diagnoses.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table13-0272989X11428516" position="float">
<label>Appendix Table 9</label>
<caption>
<p>Performance of Colposcopy among Women with an ASCUS Referral Diagnosis by Study Arm, Enrollment Cytology, and Age Quartile</p>
</caption>
<graphic alternate-form-of="table13-0272989X11428516" xlink:href="10.1177_0272989X11428516-table13.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">&lt;22 Years</th>
<th align="center" colspan="2">22–25 Years</th>
<th align="center" colspan="2">26–33 Years</th>
<th align="center" colspan="2">34+ Years</th>
<th/>
</tr>
<tr>
<th align="center" colspan="10">Sensitivity of Colposcopy for Detection of CIN3, Given HSIL+ and HC2+/Missing<sup><xref ref-type="table-fn" rid="table-fn51-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn52-0272989X11428516">b</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>8</td>
<td>75.0 (34.9–96.8)</td>
<td>13</td>
<td>84.6 (54.6–98.1)</td>
<td>9</td>
<td>55.6 (21.2–86.3)</td>
<td>4</td>
<td>50.0 (6.8–93.2)</td>
<td>0.30</td>
</tr>
<tr>
<td>HPV</td>
<td>8</td>
<td>100.0 (63.1–100.0</td>
<td>9</td>
<td>88.9 (51.8–99.7)</td>
<td>10</td>
<td>90.0 (55.5–99.75)</td>
<td>4</td>
<td>75.0 (19.4–99.4)</td>
<td>0.7</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>22</td>
<td>95.5 (77.2–99.9)</td>
<td>16</td>
<td>87.5 (61.7–98.45)</td>
<td>18</td>
<td>77.8 (52.4–93.6)</td>
<td>4</td>
<td>50.0 (6.8–93.2)</td>
<td>0.08</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn53-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.2</td>
<td/>
<td>1.0</td>
<td/>
<td>0.2</td>
<td/>
<td>1.0</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Sensitivity of Colposcopy for Detection of CIN3, Given &lt;HSIL and HC2+/Missing at Enrollment<sup><xref ref-type="table-fn" rid="table-fn51-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center">CIN3 Cases Referred, <italic>n</italic></th>
<th align="center">Sensitivity of Colposcopy (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn52-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>14</td>
<td>21.4 (4.7–50.8)</td>
<td>23</td>
<td>43.5 (23.2–65.5)</td>
<td>8</td>
<td>50.0 (15.7–84.3)</td>
<td>5</td>
<td>20.0 (0.5–71.6)</td>
<td>0.45</td>
</tr>
<tr>
<td>HPV</td>
<td>26</td>
<td>46.2 (26.6–66.6)</td>
<td>18</td>
<td>55.6 (30.8–78.5)</td>
<td>18</td>
<td>55.6 (30.8–78.5)</td>
<td>3</td>
<td>100.0 (29.2–100)</td>
<td>0.44</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn53-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.18</td>
<td/>
<td>0.54</td>
<td/>
<td>1.0</td>
<td/>
<td>0.14</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn54-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, IC arm)</td>
<td/>
<td>0.03</td>
<td/>
<td>0.03</td>
<td/>
<td>1.0</td>
<td/>
<td>0.52</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn54-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, HPV arm)</td>
<td/>
<td>0.01</td>
<td/>
<td>0.19</td>
<td/>
<td>0.10</td>
<td/>
<td>1.0</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Positive Predictive Value of Colposcopy for Detection of CIN3, Given HSIL+ and HC2+/Missing<sup><xref ref-type="table-fn" rid="table-fn51-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn52-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>11</td>
<td>54.55 (23.4–83.3)</td>
<td>17</td>
<td>64.7 (38.3–85.8)</td>
<td>9</td>
<td>55.6 (21.2–86.3)</td>
<td>3</td>
<td>66.7 (9.4–99.2)</td>
<td>0.93</td>
</tr>
<tr>
<td>HPV</td>
<td>12</td>
<td>66.7 (34.9–90.1)</td>
<td>15</td>
<td>53.3 (26.6–78.7)</td>
<td>11</td>
<td>81.8 (48.2–97.7)</td>
<td>4</td>
<td>75.0 (19.4–99.4)</td>
<td>0.54</td>
</tr>
<tr>
<td>CM (overall)</td>
<td>29</td>
<td>72.4 (52.8–87.3)</td>
<td>18</td>
<td>77.8 (52.4–93.6)</td>
<td>19</td>
<td>73.7 (48.8–90.9)</td>
<td>4</td>
<td>50.0 (6.8–93.2)</td>
<td>0.74</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn53-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.6</td>
<td/>
<td>0.32</td>
<td/>
<td>0.5</td>
<td/>
<td>1.0</td>
<td/>
</tr>
<tr>
<th align="center" colspan="10">Positive Predictive Value of Colposcopy for Detection of CIN3, Given &lt;HSIL and HC2+/Missing at Enrollment<sup><xref ref-type="table-fn" rid="table-fn51-0272989X11428516">a</xref></sup></th>
</tr>
<tr>
<th/>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center">Positive Colposcopies, <italic>n</italic></th>
<th align="center">Positive Predictive Value (95% CI)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn52-0272989X11428516">b</xref></sup></th>
</tr>
<tr>
<td>IC</td>
<td>18</td>
<td>16.7 (3.6–41.4)</td>
<td>19</td>
<td>52.6 (28.9–75.6)</td>
<td>13</td>
<td>30.8 (9.1–61.4)</td>
<td>4</td>
<td>25.0 (0.6–80.6)</td>
<td>0.13</td>
</tr>
<tr>
<td>HPV</td>
<td>31</td>
<td>38.7 (21.85–57.8)</td>
<td>15</td>
<td>66.7 (38.4–88.2)</td>
<td>18</td>
<td>55.6 (30.8–78.5)</td>
<td>6</td>
<td>50.0 (11.8–88.2)</td>
<td>0.32</td>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn53-0272989X11428516">c</xref></sup></td>
<td/>
<td>0.20</td>
<td/>
<td>0.50</td>
<td/>
<td>0.28</td>
<td/>
<td>0.57</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn54-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, IC arm)</td>
<td/>
<td>0.05</td>
<td/>
<td>0.52</td>
<td/>
<td>0.38</td>
<td/>
<td>0.49</td>
<td/>
</tr>
<tr>
<td><italic>P</italic> value<sup><xref ref-type="table-fn" rid="table-fn54-0272989X11428516">d</xref></sup> (&lt;HSIL v. HSIL+, HPV arm)</td>
<td/>
<td>0.17</td>
<td/>
<td>0.71</td>
<td/>
<td>0.23</td>
<td/>
<td>0.57</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn50-0272989X11428516">
<p>Note: Colposcopic performance in the IC and HPV arms is evaluated at the enrollment visit and in the CM arm is evaluated at the enrollment, 6-month, and 12-month visits combined. We report exact binomial confidence intervals. HSIL+ = high-grade squamous intraepithelial lesion on cytology; &lt;HSIL = less than high-grade squamous intraepithelial lesion on cytology (i.e., normal, ASCUS, ASC-H, LSIL); CIN3 = cervical intraepithelial neoplasia grade 3; HC2+ = Hybrid Capture 2 positive or missing at enrollment in the IC and HPV arms or at the visit of colposcopic referral for HSIL+ in the CM arm. We excluded 1 cancer case in the CM arm that was censored at enrollment but included 1 cancer case in women ≥34 years in the IC arm that was not detected until 12 months.</p>
</fn>
<fn id="table-fn51-0272989X11428516">
<label>a.</label>
<p>“Sensitivity of colposcopy for detection of CIN3” is defined as the probability of a clinical center histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, and 12-month visits in the CM arm) among women in an arm who have a worst 2-year QC pathology group diagnosis of CIN3 who were referred to colposcopy. For the CM arm, we present results overall and by visit; the number of CIN3 cases by visit represents the number referred due to HSIL+ at that visit. “Positive predictive value of colposcopy for detection of CIN3” is defined as the probability of having a worst 2-year QC pathology group diagnosis of CIN3 among women who received a histopathological diagnosis of CIN2+ (at enrollment in the IC and HPV arms; at enrollment, 6-month, or 12-month visits in the CM arm) at a clinical center. Women without enrollment cytology results were excluded.</p>
</fn>
<fn id="table-fn52-0272989X11428516">
<label>b.</label>
<p>Fisher exact test, comparing across age quartiles.</p>
</fn>
<fn id="table-fn53-0272989X11428516">
<label>c.</label>
<p>Fisher exact test, comparing across study arms.</p>
</fn>
<fn id="table-fn54-0272989X11428516">
<label>d.</label>
<p>Fisher exact test, comparing across cytology interpretations (&lt;HSIL v. HSIL+) within a study arm.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table14-0272989X11428516" position="float">
<label>Appendix Table 10</label>
<caption>
<p>Costs, Effectiveness, and Cost-Effectiveness of Each Management Strategy for Detection of CIN3 for Steps 1 to 3 among Women with an ASCUS Referral Diagnosis</p>
</caption>
<graphic alternate-form-of="table14-0272989X11428516" xlink:href="10.1177_0272989X11428516-table14.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="16">Step 1: Unadjusted ALTS Data</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;22 Years</th>
<th align="center" colspan="4">22–25 Years</th>
<th align="center" colspan="4">26–33 Years</th>
<th align="center" colspan="4">≥34 Years</th>
</tr>
<tr>
<th align="left">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>CM first visit</td>
<td>118.11</td>
<td>49.2</td>
<td>—</td>
<td>CM first visit</td>
<td>111.66</td>
<td>30.4</td>
<td>—</td>
<td>CM first visit</td>
<td>110.75</td>
<td>39.0</td>
<td>—</td>
<td>HPV</td>
<td>73.28</td>
<td>20.3</td>
<td>—</td>
</tr>
<tr>
<td>HPV</td>
<td>149.99</td>
<td>69.2</td>
<td>$1590</td>
<td>HPV</td>
<td>142.28</td>
<td>66.0</td>
<td>$860</td>
<td>HPV</td>
<td>120.91</td>
<td>64.1</td>
<td>$400</td>
<td>CM first visit</td>
<td>100.15</td>
<td>3.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM second visit</td>
<td>189.52</td>
<td>64.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>186.03</td>
<td>30.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.84</td>
<td>42.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.46</td>
<td>3.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>191.73</td>
<td>32.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>193.69</td>
<td>76.9</td>
<td>$4720</td>
<td>IC</td>
<td>195.38</td>
<td>36.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.39</td>
<td>10.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM third visit</td>
<td>289.84</td>
<td>72.0</td>
<td>$49,950</td>
<td>CM third visit</td>
<td>255.74</td>
<td>53.2</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>257.12</td>
<td>42.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>270.00</td>
<td>7.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="16">Step 2a: Adjustment for Variation in Prevalence of CIN3</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;22 Years</th>
<th align="center" colspan="4">22–25 Years</th>
<th align="center" colspan="4">26–33 Years</th>
<th align="center" colspan="4">≥34 Years</th>
</tr>
<tr>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM first visit</td>
<td>116.55</td>
<td>42.1</td>
<td>—</td>
<td>CM first visit</td>
<td>111.77</td>
<td>31.0</td>
<td>—</td>
<td>CM first visit</td>
<td>110.50</td>
<td>37.9</td>
<td>—</td>
<td>HPV</td>
<td>75.06</td>
<td>31.6</td>
<td>—</td>
</tr>
<tr>
<td>HPV</td>
<td>147.96</td>
<td>61.1</td>
<td>$1650</td>
<td>HPV</td>
<td>142.07</td>
<td>74.4</td>
<td>$700</td>
<td>HPV</td>
<td>118.52</td>
<td>57.4</td>
<td>$410</td>
<td>CM first visit</td>
<td>99.86</td>
<td>3.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM second visit</td>
<td>187.80</td>
<td>55.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>186.09</td>
<td>31.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.66</td>
<td>40.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.28</td>
<td>3.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>191.17</td>
<td>44.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>192.94</td>
<td>68.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.98</td>
<td>43.8</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.12</td>
<td>8.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM third visit</td>
<td>248.61</td>
<td>61.6</td>
<td>$201,300</td>
<td>CM third visit</td>
<td>255.87</td>
<td>54.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>257.00</td>
<td>40.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>269.86</td>
<td>6.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="16">Step 2b: Adjustment for Ascertainment Bias (Inferior Performance in IC Arm)</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;22 Years</th>
<th align="center" colspan="4">22–25 Years</th>
<th align="center" colspan="4">26–33 Years</th>
<th align="center" colspan="4">≥34 Years</th>
</tr>
<tr>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM first visit</td>
<td>118.11</td>
<td>49.2</td>
<td>—</td>
<td>CM first visit</td>
<td>111.66</td>
<td>30.4</td>
<td>—</td>
<td>CM first visit</td>
<td>110.75</td>
<td>39.0</td>
<td>—</td>
<td>HPV</td>
<td>73.28</td>
<td>20.3</td>
<td>—</td>
</tr>
<tr>
<td>HPV</td>
<td>149.99</td>
<td>69.2</td>
<td>$1590</td>
<td>HPV</td>
<td>142.28</td>
<td>66.0</td>
<td>$860</td>
<td>HPV</td>
<td>120.91</td>
<td>64.1</td>
<td>$400</td>
<td>CM first visit</td>
<td>100.15</td>
<td>3.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM second visit</td>
<td>189.52</td>
<td>64.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>186.03</td>
<td>30.4</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.84</td>
<td>42.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.46</td>
<td>3.5</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>191.36</td>
<td>43.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>191.31</td>
<td>86.7</td>
<td>$2370</td>
<td>IC</td>
<td>195.49</td>
<td>36.6</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.51</td>
<td>24.3</td>
<td>$30,310</td>
</tr>
<tr>
<td>CM third visit</td>
<td>289.84</td>
<td>72.0</td>
<td>$49,950</td>
<td>CM third visit</td>
<td>255.74</td>
<td>53.2</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>257.12</td>
<td>42.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>270.00</td>
<td>7.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<th align="center" colspan="16">Step 3: Simultaneous Adjustment for Variation in Prevalence of CIN3 and Ascertainment Bias</th>
</tr>
<tr>
<th align="center" colspan="4">&lt;22 Years</th>
<th align="center" colspan="4">22–25 Years</th>
<th align="center" colspan="4">26–33 Years</th>
<th align="center" colspan="4">≥34 Years</th>
</tr>
<tr>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
<th align="center">Strategy</th>
<th align="center">Costs<sup><xref ref-type="table-fn" rid="table-fn56-0272989X11428516">a</xref></sup></th>
<th align="center">Effects<sup><xref ref-type="table-fn" rid="table-fn57-0272989X11428516">b</xref></sup></th>
<th align="center">ICER<sup><xref ref-type="table-fn" rid="table-fn58-0272989X11428516">c</xref></sup></th>
</tr>
<tr>
<td>CM first visit</td>
<td>116.55</td>
<td>42.1</td>
<td>—</td>
<td>CM first visit</td>
<td>111.77</td>
<td>31.0</td>
<td>—</td>
<td>CM first visit</td>
<td>110.50</td>
<td>37.9</td>
<td>—</td>
<td>HPV</td>
<td>75.06</td>
<td>31.6</td>
<td>—</td>
</tr>
<tr>
<td>HPV</td>
<td>147.96</td>
<td>61.1</td>
<td>$1650</td>
<td>HPV</td>
<td>142.07</td>
<td>74.4</td>
<td>$700</td>
<td>HPV</td>
<td>118.52</td>
<td>57.4</td>
<td>$410</td>
<td>CM first visit</td>
<td>99.86</td>
<td>3.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM second visit</td>
<td>187.80</td>
<td>55.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>186.09</td>
<td>31.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.66</td>
<td>40.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM second visit</td>
<td>188.28</td>
<td>3.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>IC</td>
<td>190.66</td>
<td>60.0</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>190.82</td>
<td>76.9</td>
<td>$19,500</td>
<td>IC</td>
<td>195.11</td>
<td>43.8</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>IC</td>
<td>194.21</td>
<td>19.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
<tr>
<td>CM third visit</td>
<td>248.61</td>
<td>61.6</td>
<td>$201,300</td>
<td>CM third visit</td>
<td>255.87</td>
<td>54.3</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>257.00</td>
<td>40.9</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
<td>CM third visit</td>
<td>269.86</td>
<td>6.1</td>
<td>—<sup><xref ref-type="table-fn" rid="table-fn59-0272989X11428516">d</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn55-0272989X11428516">
<p>Note: Strategies are presented in order of increasing cost. ICER = incremental cost-effectiveness ratio; IC = immediate colposcopy arm; HPV = HPV DNA triage arm; CM = conservative management arm; CIN3 = cervical intraepithelial neoplasia grade 3.</p>
</fn>
<fn id="table-fn56-0272989X11428516">
<label>a.</label>
<p>Costs per hypothetical woman in the model are reported in 2010 US dollars.</p>
</fn>
<fn id="table-fn57-0272989X11428516">
<label>b.</label>
<p>Effects are reported as cases of CIN3+ detected per 1000 women in the model.</p>
</fn>
<fn id="table-fn58-0272989X11428516">
<label>c.</label>
<p>ICERs are reported as the cost per case of CIN3+ detected ($/case detected).</p>
</fn>
<fn id="table-fn59-0272989X11428516">
<label>d.</label>
<p>Dominated strategy (i.e., was more costly and less effective than other strategies or had a higher ICER than more effective strategies).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-0272989X11428516">
<title>Guidance for Adjusting RCT Data When Individual-Level Data Are Unavailable</title>
<p>Our adjustment of RCT data relied on individual-level data from ALTS. It would have been difficult to undertake the present analysis to explore optimal management of LSIL by age group without individual-level data, given that the main published findings from the trial were not stratified by age. Age-based evaluation aside, we could have adjusted ALTS data (albeit more crudely) without access to individual-level data from the trial. We offer the following example as guidance to analysts seeking to adjust RCT data for economic evaluation without access to a trial dataset.</p>
<p>In the main publication on management of women with LSIL, the ALTS Group reported the relatively higher prevalence of CIN3 in the HPV arm relative to the IC and CM arms (although these were not significantly different).<sup><xref ref-type="bibr" rid="bibr25-0272989X11428516">25</xref></sup> The IC arm’s lower sensitivity for CIN3 relative to the HPV arm was also noted (this difference was not significant either). As we demonstrate in the article, individual-level data allowed us to discern statistically significant differences in colposcopic performance within a clinical subgroup (HC2+, &lt;HSIL).</p>
<p>However, even without individual-level data to examine and support mechanisms for potential bias or random error, an analyst could still note that the prevalence of CIN3 and colposcopic performance, both critical determinants of effectiveness/cost-effectiveness of management strategies, were somewhat different between arms. Upon careful examination of trial design, which was well documented by the investigators,<sup><xref ref-type="bibr" rid="bibr15-0272989X11428516">15</xref></sup> an analyst could also hypothesize reasons for the unexpectedly low performance of colposcopy in the IC arm (i.e., a potential bias stemming from provider awareness of either arm or test result based on lag time for the colposcopic visit in the HPV and CM arms) and for differences in CIN3 prevalence (i.e., the use of 2-year cumulative CIN3 diagnosis as the primary outcome). Without individual-level data, adjustments for CIN3 prevalence would have been similar, based on figures published by study investigators.<sup><xref ref-type="bibr" rid="bibr25-0272989X11428516">25</xref></sup> Adjustment for provider bias would necessarily have been cruder. For instance, the investigators published the average HC2 positivity in CIN3 combined across all arms, which could have been used to roughly stratify women in the IC arm into those with a similar clinical profile to women referred to colposcopy in the HPV arm and those with a dissimilar profile. We could have adjusted colposcopic performance in the IC arm to resemble the HPV arm among HC2+ women and made no adjustment among HC2– women. A more liberal adjustment might involve using the same colposcopic sensitivity in the IC and HPV arms. These experiments would at least provide a sense of how cost-effectiveness results are impacted and what the range of uncertainty is, depending on the extent of the bias. If such an adjustment contrasted from the unadjusted analysis and indicated a potential role for IC, then the analyst would be aware that the foundation of the unadjusted economic evaluation was tenuous.</p>
</sec>
<sec id="section19-0272989X11428516">
<title>Appendix Notes</title>
<p>a. In this analysis of ASCUS women, as in the LSIL analysis, we excluded women with missing QC pathology diagnoses. We also excluded 1 case of cancer in the CM arm that was identified as CIN3 at enrollment. We included 1 case of cancer in the IC arm that was not detected until 12 months and was therefore considered a major failure of the arm.</p>
<p>b. Model assumptions are comparable to those in the LSIL analysis. We assume reflex HPV testing.</p>
</sec>
</app>
</app-group>
<fn-group>
<fn fn-type="supported-by">
<p>This work was supported by the National Cancer Institute (R01 CA93435), the National Institutes of Health/National Cancer Institute Intramural Research Program, and the National Cancer Institute, National Institutes of Health, Department of Health and Human Services (contract no. CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159, and CN-55105). PEC has received donations of HPV tests from Qiagen and serves on a data safety and monitoring committee for Merck, the manufacturer of Gardasil, for which he receives compensation.</p>
</fn>
</fn-group>
<notes>
<fn-group>
<fn fn-type="other" id="fn1-0272989X11428516">
<label>a.</label>
<p>The name of the study, ALTS, includes reference to “ASCUS” as defined by the 1988 Bethesda System. However, in this article, we follow the 2001 Bethesda System and refer to the cytology result as “ASCUS”.</p>
</fn>
<fn fn-type="other" id="fn2-0272989X11428516">
<label>b.</label>
<p>Due to the imperfect sensitivity of colposcopy, it is uncertain whether CIN3 detected late in the study may have missed prevalent or newly incident cases. However, a review of all records for CIN3 cases suggested that many represented missed prevalent disease rather than incident CIN3 (The ALTS Group 2003). Given the lack of a gold standard, the detection of CIN3 at any time during the 2 years of the trial (i.e., worst 2-year QC diagnosis of CIN3) is the best proxy available for the presence of precancer at enrollment.</p>
</fn>
<fn fn-type="other" id="fn3-0272989X11428516">
<label>c.</label>
<p>There appears to have been statistically significant regression of missed prevalent CIN2 in the CM arm relative to the IC arm over the 2 years of the trial (comparisons to the HPV arm were not possible due to small numbers) (The ALTS Group 2003). Despite modest gains in statistical power to detect differences in disease prevalence by including CIN2 as an end point of interest (Appendix <xref ref-type="table" rid="table2-0272989X11428516">Table 2</xref>), the tendency of CIN2 to regress makes it an unreliable indication of precancer.</p>
</fn>
<fn fn-type="other" id="fn4-0272989X11428516">
<label>d.</label>
<p>To be consistent with the protocol for the HPV arm, we assumed the 3 women with CIN3 in the IC arm with missing enrollment HC2 results were defaulted positive and included their colposcopy results in our analysis of performance. In the CM arm, all women with CIN3 who were HSIL+ and sent to colposcopy were HC2+.</p>
</fn>
</fn-group>
</notes>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X11428516">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eccles</surname><given-names>M</given-names></name>
<name><surname>Grimshaw</surname><given-names>J</given-names></name>
<name><surname>Campbell</surname><given-names>M</given-names></name>
<name><surname>Ramsay</surname><given-names>C</given-names></name>
</person-group>. <article-title>Research designs for studies evaluating the effectiveness of change and improvement strategies</article-title>. <source>Qual Saf Health Care</source>. <year>2003</year>;<volume>12</volume>:<fpage>47</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X11428516">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Concato</surname><given-names>J</given-names></name>
<name><surname>Shah</surname><given-names>N</given-names></name>
<name><surname>Horwitz</surname><given-names>RI</given-names></name>
</person-group>. <article-title>Randomized, controlled trials, observational studies, and the hierarchy of research designs</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>342</volume>:<fpage>1887</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr3-0272989X11428516">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rittenhouse</surname><given-names>BE</given-names></name>
</person-group>. <article-title>The relevance of searching for effects under a clinical-trial lamppost: a key issue. Med Decis Making</article-title>. <year>1995</year>;<volume>14</volume>:<fpage>348</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X11428516">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rittenhouse</surname><given-names>BE</given-names></name>
</person-group>. <article-title>Exorcising protocol-induced spirits: making the clinical trial relevant for economics</article-title>. <source>Med Decis Making</source>. <year>1997</year>;<volume>17</volume>:<fpage>331</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X11428516">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>M</given-names></name>
</person-group>. <article-title>Experimental versus observational data in the economic evaluation of pharmaceuticals</article-title>. <source>Med Decis Making</source>. <year>1998</year>;<volume>18</volume>:<fpage>512</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X11428516">
<label>6.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Eddy</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Should we change the rules for evaluating medical technologies?</article-title> In: <person-group person-group-type="editor">
<name><surname>Gelijns</surname><given-names>AC</given-names></name>
</person-group>, ed. <source>Modern Methods of Clinical Investigation</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academy Press</publisher-name>; <year>1990</year>.</citation>
</ref>
<ref id="bibr7-0272989X11428516">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>BJ</given-names></name>
<name><surname>Anderson</surname><given-names>DR</given-names></name>
<name><surname>Goeree</surname><given-names>R</given-names></name>
</person-group>. <article-title>Cost-effectiveness of enoxaparin vs. warfarin prophylaxis against deep-vein thrombosis after total hip replacement</article-title>. <source>Can Med Assoc J</source>. <year>1994</year>;<volume>150</volume>:<fpage>1083</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X11428516">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Castle</surname><given-names>PE</given-names></name>
<name><surname>Jeronimo</surname><given-names>J</given-names></name>
<name><surname>Rodriguez</surname><given-names>AC</given-names></name>
<name><surname>Wacholder</surname><given-names>S</given-names></name>
</person-group>. <article-title>Human papillomavirus and cervical cancer</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>:<fpage>890</fpage>–<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X11428516">
<label>9.</label>
<citation citation-type="journal">
<collab>American College of Obstetricians and Gynecologists</collab>. <article-title>ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol</article-title>. <year>2009</year>;<volume>114</volume>:<fpage>1409</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X11428516">
<label>10.</label>
<citation citation-type="gov">
<article-title>National Cancer Institute. Fact sheet: Pap test</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov/cancertopics/factsheet/Detection/Pap-test">http://www.cancer.gov/cancertopics/factsheet/Detection/Pap-test</ext-link></comment></citation>
</ref>
<ref id="bibr11-0272989X11428516">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>D</given-names></name>
<name><surname>Davey</surname><given-names>D</given-names></name>
<name><surname>Kurman</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>The 2001 Bethesda System: terminology for reporting results of cervical cytology</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>:<fpage>2114</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X11428516">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Wentzensen</surname><given-names>N</given-names></name>
<name><surname>Wacholder</surname><given-names>S</given-names></name>
<name><surname>Kinney</surname><given-names>W</given-names></name>
<name><surname>Gage</surname><given-names>JC</given-names></name>
<name><surname>Castle</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Human papillomavirus testing in the prevention of cervical cancer</article-title>. <source>J Natl Cancer Inst</source>. <year>2011</year>;<volume>103</volume>:<fpage>368</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X11428516">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Kjaer</surname><given-names>SK</given-names></name>
</person-group>. <article-title>Natural history of anogenital human papillomavirus infection and neoplasia</article-title>. <source>J Natl Cancer Inst Monogr</source>. <year>2003</year>;<volume>31</volume>:<fpage>14</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X11428516">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Solomon</surname><given-names>D</given-names></name>
</person-group>. <article-title>Findings to date from the ASCUS-LSIL Triage Study (ALTS)</article-title>. <source>Arch Pathol Lab Med</source>. <year>2003</year>;<volume>127</volume>:<fpage>946</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X11428516">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Adrianza</surname><given-names>ME</given-names></name>
</person-group>. <article-title>ASCUS-LSIL Triage Study: design, methods and characteristics of trial participants</article-title>. <source>Acta Cytol</source>. <year>2000</year>;<volume>44</volume>(<issue>5</issue>):<fpage>726</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X11428516">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>D</given-names></name>
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Tarone</surname><given-names>R</given-names></name>
</person-group>. <article-title>Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial</article-title>. <source>J Natl Cancer Inst</source>. <year>2001</year>;<volume>93</volume>:<fpage>293</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X11428516">
<label>17.</label>
<citation citation-type="journal">
<collab>The ASCUS-LSIL Triage Study (ALTS) Group</collab>. <article-title>Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance</article-title>. <source>Am J Obstet Gynecol</source>. <year>2003</year>;<volume>188</volume>:<fpage>1383</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X11428516">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JJ</given-names></name>
<name><surname>Wright</surname><given-names>TC</given-names></name>
<name><surname>Goldie</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>:<fpage>2382</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr19-0272989X11428516">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kulasingam</surname><given-names>SL</given-names></name>
<name><surname>Kim</surname><given-names>JJ</given-names></name>
<name><surname>Lawrence</surname><given-names>WF</given-names></name>
<etal/>
</person-group>. <article-title>Cost-effectiveness analysis based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)</article-title>. <source>J Natl Cancer Inst</source>. <year>2006</year>;<volume>98</volume>:<fpage>92</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X11428516">
<label>20.</label>
<citation citation-type="book">
<collab>American College of Obstetricians and Gynecologists</collab>. <article-title>ACOG Practice Bulletin No</article-title>. <volume>99</volume>: <publisher-name>management of abnormal cervical cytology and histology. Obstet Gynecol</publisher-name>. <year>2008</year>;<volume>112</volume>:<fpage>1419</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X11428516">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherman</surname><given-names>ME</given-names></name>
<name><surname>Schiffman</surname><given-names>M</given-names></name>
<name><surname>Cox</surname><given-names>JT</given-names></name>
</person-group>. <article-title>Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS)</article-title>. <source>J Natl Cancer Inst</source>. <year>2002</year>;<volume>94</volume>:<fpage>102</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X11428516">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arbyn</surname><given-names>M</given-names></name>
<name><surname>Martin-Hirsch</surname><given-names>P</given-names></name>
<name><surname>Buntinx</surname><given-names>F</given-names></name>
<name><surname>Van Ranst</surname><given-names>M</given-names></name>
<name><surname>Paraskevaidis</surname><given-names>E</given-names></name>
<name><surname>Dillner</surname><given-names>J</given-names></name>
</person-group>. <article-title>Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate</article-title>. <source>J Cell Molec Med</source>. <year>2009</year>;<volume>13</volume>:<fpage>648</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X11428516">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brismar-Wendel</surname><given-names>S</given-names></name>
<name><surname>Froberg</surname><given-names>M</given-names></name>
<name><surname>Hjerpe</surname><given-names>A</given-names></name>
<name><surname>Andersson</surname><given-names>S</given-names></name>
<name><surname>Johansson</surname><given-names>B</given-names></name>
</person-group>. <article-title>Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions</article-title>. <source>Br J Cancer</source>. <year>2009</year>;<volume>101</volume>:<fpage>511</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X11428516">
<label>24.</label>
<citation citation-type="journal">
<collab>Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group</collab>. <article-title>Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial</article-title>. <source>J Natl Cancer Inst</source>. <year>2000</year>;<volume>92</volume>:<fpage>397</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X11428516">
<label>25.</label>
<citation citation-type="journal">
<collab>The ASCUS-LSIL Triage Study (ALTS) Group</collab>. <article-title>A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations</article-title>. <source>Am J Obstet Gynecol</source>. <year>2003</year>;<volume>188</volume>:<fpage>1393</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X11428516">
<label>26.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Gold</surname><given-names>MR</given-names></name>
<name><surname>Siegel</surname><given-names>JE</given-names></name>
<name><surname>Russell</surname><given-names>LB</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>, eds. <article-title>Cost-Effectiveness in Health and Medicine</article-title>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr27-0272989X11428516">
<label>27.</label>
<citation citation-type="web">
<person-group person-group-type="editor">
<name><surname>Elliott</surname><given-names>AC</given-names></name>
<name><surname>Reisch</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Implementing a multiple comparison test for proportions in a 2xc crosstabulation in SAS</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www2.sas.com/proceedings/sugi31/204-31.pdf">http://www2.sas.com/proceedings/sugi31/204-31.pdf</ext-link></comment></citation>
</ref>
<ref id="bibr28-0272989X11428516">
<label>28.</label>
<citation citation-type="gov">
<collab>Centers for Medicare and Medicaid Services</collab>. <article-title>Clinical diagnostic laboratory fee schedule: April 2010</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cms.gov/ClinicalLabFeesched/02_clinlab.asp">http://www.cms.gov/ClinicalLabFeesched/02_clinlab.asp</ext-link></comment></citation>
</ref>
<ref id="bibr29-0272989X11428516">
<label>29.</label>
<citation citation-type="gov">
<collab>Centers for Medicare and Medicaid Services</collab>. <article-title>Physician fee relative value file: January 2010 (revised)</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cms.gov/physicianfeesched/pfsrvf/ItemDetail.asp?ItemID=CMS1230197">http://www.cms.gov/physicianfeesched/pfsrvf/ItemDetail.asp?ItemID=CMS1230197</ext-link></comment></citation>
</ref>
<ref id="bibr30-0272989X11428516">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pretorius</surname><given-names>RG</given-names></name>
<name><surname>Belinson</surname><given-names>JL</given-names></name>
<name><surname>Zhang</surname><given-names>WH</given-names></name>
<name><surname>Burchette</surname><given-names>RF</given-names></name>
<name><surname>Elson</surname><given-names>P</given-names></name>
<name><surname>Qiao</surname><given-names>YL</given-names></name>
</person-group>. <article-title>The colposcopic impression: is it influenced by the colposcopist’s knowledge of the findings on the referral Papanicolaou smear?</article-title> <source>J Reprod Med</source>. <year>2001</year>;<volume>46</volume>:<fpage>724</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X11428516">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pretorius</surname><given-names>RG</given-names></name>
<name><surname>Zhang</surname><given-names>WH</given-names></name>
<name><surname>Belinson</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse</article-title>. <source>Am J Obstet Gynecol</source>. <year>2004</year>;<volume>191</volume>:<fpage>430</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr32-0272989X11428516">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeronimo</surname><given-names>J</given-names></name>
<name><surname>Massad</surname><given-names>S</given-names></name>
<name><surname>Schiffman</surname><given-names>M</given-names></name>
</person-group>. <article-title>Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type</article-title>. <source>Am J Obstet Gynecol</source>. <year>2007</year>;<volume>197</volume>:47.e1–<fpage>8</fpage>.</citation>
</ref>
<ref id="bibr33-0272989X11428516">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gage</surname><given-names>JC</given-names></name>
<name><surname>Hanson</surname><given-names>VW</given-names></name>
<name><surname>Abbey</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Number of cervical biopsies and sensitivity of colposcopy</article-title>. <source>Obstet Gynecol</source>. <year>2006</year>;<volume>108</volume>:<fpage>264</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr34-0272989X11428516">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buck</surname><given-names>C</given-names></name>
<name><surname>Donner</surname><given-names>A</given-names></name>
</person-group>. <article-title>The design of controlled experiments in the evaluation of non-therapeutic interventions</article-title>. <source>J Chron Dis</source>. <year>1982</year>;<volume>35</volume>:<fpage>531</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X11428516">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eddy</surname><given-names>DM</given-names></name>
</person-group>. <article-title>The confidence profile method: a Bayesian method for assessing health technologies</article-title>. <source>Oper Res</source>. <year>1989</year>;<volume>37</volume>:<fpage>210</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X11428516">
<label>36.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Eddy</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Top 10 projects</article-title>. <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.davidmeddy.com/Top10projects.htm#The%20Confidence%20Profile%20Method">http://www.davidmeddy.com/Top10projects.htm#The%20Confidence%20Profile%20Method</ext-link></comment></citation>
</ref>
</ref-list>
</back>
</article>